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Abstract 
Small molecules are of great importance in drug discovery currently. The first three 
chapters discussed the design, synthesis and bio-evaluation of three different classes of small 
molecules and exploration of their biological targets. Triacsin C analogs were designed as long 
chain fatty acyl-CoA synthetase (ACSL) inhibitors for attenuating ischemia and reperfusion (I/R) 
injury. Oxadiazole derivatives were designed as T-type calcium channel inhibitors, which have 
potential application in the treatment of seizure and epilepsy. Tricyclic pyrone derivatives were 
reported as anti-Alzheimer lead compounds in previous research done by the Hua group. TP70 
and CP2 were synthesized to explore their pharmacokinetics properties. 
Chapter 4 described chiral-substituted poly-N-vinylpyrrolidones (CSPVP) supported 
Cu/Au nanoclusters mediation of cyclization reaction of 5-substituted nona-1,8-dien-5-ols. A 
five-member cyclized lactone possessing a stereogenic tetrasubstituted carbon center was formed 
in a one-step Cu/Au nanoclusters-hydrogen peroxide oxidation reaction. This developed a novel 
and simple method to synthesize tetrasubstituted carbon stereogenic center. Drawbacks of the 
method in my initial study were low reaction yield and moderate enantioselectivity. The 
chemical yield and enantioselectivity have been significantly improved by introducing bulkier 
substitution in C3 and C4 positions of CSPVP according to the updates of ongoing research. 
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1 
Chapter 1 - Design, synthesis and bio-evaluation of triacsin C 
analogs as long chain fatty acyl-CoA synthetase inhibitors 
attenuating ischemia and reperfusion injury 
 1.1 Background and significance 
 1.1.1 Long chain fatty acyl-CoA synthetase (ACSL) 
Long chain fatty acyl-CoA (ACSL) is an enzyme which can catalyze formation of fatty acyl CoA 
in a two-step process (as shown in Figure 1.1) through a fatty acyl adenyl intermediate.
1
 ACSL 
families are of great importance in the fatty acid metabolism. Palmitoyl-CoA is formed when 
ACSL catalyzing acylation of palmitic acid and the formed palmitoyl-CoA is an important 
intermediate in the palmitoylation of protein.
2
 During protein palmitoylation (see Figure 1.2), in 
the presence of palmitoyl-CoA and palmitoyl acyltransferase (PAT), cysteine thiol groups on a 
substrate protein (usually membrane proteins) are converted to palmitoyl thioesters, which 
contribute to increased hydrophobicity of the protein.
3
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Figure 1.1. Long chain fatty acyl-CoA synthetase (ACSL) catalyzed formation of fatty acyl 
CoA. 
 
2 
 
Figure 1.2. General procedure for protein palmitoylation. 
 
 1.1.2 Ischemia and reperfusion (I/R) injury 
Ischemia is the cutoff of blood supply to a tissue or certain organs from blood vessels. It often 
leads to the formation of stroke, infarction and other thrombotic events.
3
 Prolonged ischemia will 
lead to cell death.
3
 One way to decrease the injury of ischemia is to restore blood to the 
thrombosis tissue. However, studies have shown that instead of attenuating the injury, usually a 
higher extent of injury occurs.
4,5
 It is believed that ischemia leads to accumulation of aerobic 
metabolites, which undergo rapid reactions in the presence of reperfused oxygen.
6-8
 The injury 
caused by the reperfusion of blood to ischemia tissue is called ischemia and reperfusion (I/R) 
injury and it’s often featured with cascade of intracellular events, such as reduced nitric oxide 
level and leukocyte recruitment.
9
 Among various intracellular events, the translocation of cell 
adhesion molecules induced inflammatory response greatly attribute to the I/R injury.
10,11
 Thus, 
inhibiting the inflammation response is found to be a novel strategy towards inhibition of I/R 
injury. 
 
 1.1.3 Inhibition of ACSL and I/R injury 
As reported, leukocyte recruitment is the key feature of inflammation responses and it starts with 
the translocation of cell adhesion molecules.
12
 Palmitoylation of membrane proteins (see Figure 
1.2 for protein palmitoylation) results in increased hydrophobicity of proteins and activates cell 
3 
adhesion molecules by transferring them from blood plasma to endothelia membrane.
2
 The 
presence of palmitoyl-CoA is necessary in protein palmitoylation, thus inhibition of the 
formation of palmitoyl-CoA will lead to the inhibition of protein palmitoylation, which 
eventually leads to attenuation of I/R injury as shown in Figure 1.3. 
 
 
Figure 1.3. Relationship between inhibition of ACSL and I/R injury. 
 
 1.1.4 Triacsin C 
Triacsin C is a known potent ACSL inhibitor.
13,14
 According to previous study done in Hua 
group
15
, its analogs have both ACSL inhibition ability and good anti-rotavirus activity. Studies 
reported by Blakeman et. al.
16,17
 found that triacsin C improved cardiac function after ischemia in 
rat model, which supported the hypothesis that suppressing ACSL function could reduce I/R 
injury. 
 
4 
The total synthesis of triacsin C has been reported by Tanaka et al.
18
 in 1982, and until now it is 
the only reported total synthesis method with extremely low yield (0.6%) in the last step 
(Scheme 1.1). With such a low yield, it is not affordable to prepare tracsin C for further bio-
evaluation utilizing this reported total synthesis The hydroxyl triazene is a reactive moiety which 
makes it difficult to explore synthetic approach. In addition, the unstable hydroxyl triazene 
structural moiety implies that triacsin C has poor drug like properties. The development of new 
triacsin C analogs with better drug-like properties and more straight-forward synthetic method is 
needed. 
O
(E,E,E)-2,4,7-undecatrien-1-al
H2NNH2
N NH2
Si Cla)
b) N2O3
N
N
N
OH
Triacsin C
,Et3N
(Yield 69%)
(Yield 0.6%)  
Scheme 1.1. Last two steps of the reported total synthesis of triacsin C (Tanaka et al. 
1982
18
). 
 
 1.2 Research objectives 
Research objective 1: Discover more straight forward approach towards the synthesis of a small 
library of triacsin C analogs. 
Research objective 2: Screen designed small molecules for their ACSL inhibitory activity and 
study the structure-activity relationship (SAR). (This biological study was performed in our 
collaborator, Dr. Weis group) 
Research objective 3: Study the inhibition of leukocyte recruitment of hit ACSL inhibitors and 
evaluate the feasibility of using ACSL inhibitor to reduce ischemia and reperfusion injury. (This 
biological study was performed in our collaborator, Dr. Young group) 
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 1.3 Molecular design and synthetic routes 
 1.3.1 Molecular design: Lipinski rules and Veber rules 
Drug design can not only be focused on the optimization of pharmacodynamics properties, the 
molecular properties are also of great importance, or with the hit molecules may be very potent 
but with poor drug-like properties and cannot pass through all the clinical trials. Veber rules and 
Lipinski rules are summarized based on the discovered drug candidates and are directions to 
follow to get molecules with good drug-like properties. According to Lipinski rules
19
, it is likely 
that designed molecules (except biological transporters) will have poor absorption or permeation 
if they possess any of the properties: molecule has more than 5 H-bond donors or more than 10 
H-bond acceptor; molecular weight above 500 or log P value above 5. Veber et al.
20
 studied the 
relationship between molecular structures and oral bioavailability in rats. Molecules are likely to 
have good bioavailability in rats if they have less than 10 rotatable bonds, less than 140 Å
2
 polar 
surface area or less than twelve total H-bonds. Generally, Veber rules and Lipinski rules are 
following as basic guide lines when conducting molecular designs. 
 
 1.3.2 Bioisosteric replacement strategy 
Bioisosteres were defined as “groups or molecules which have chemical and physical similarities 
producing broadly similar biological effects” by Thornber in 197921. Bioisosteric replacement 
has effect on changing different molecular properties, such as size, polarity, reactivity, and 
others, thus lead to improvements towards selectivity, solubility, stability, safety profile and 
straight forward synthetic approach
22
. Bioisosteric replacement is a useful strategy in the 
discovery of lead compounds. 
O
OH
Palmitic acid
N
N
N
OH
Triacsin C  
Figure 1.4. Chemical structures of triacsin C and palmitic acid. 
 
Triacsin (as shown in Figure 1.4) is a known nonspecific long chain fatty acyl CoA synthetase 
(ACSL) inhibitor.
16,23
 Bioisosteric replacement is a replacement of a bioactive group to a 
6 
different functional group and this strategy was applied in the design of triacsin C analogs in 
order to obtain hit molecules with increased stability. 
 
Triacsin C was found to be acting like a substrate binding site blocker when inhibiting ACSL
13
. 
The availability of palmitoyl-CoA is need for protein to go through palmitoylation.
2
 Tracsin C 
can act as a substrate competitor against palmitic acid and prevent the formation of palmitoyl-
CoA. Both triacsin C and palmitic acid have long aliphatic tails and hydrophilic head groups. In 
the structural analysis of triacsin C, the hydroxyl triazene is mimicking the acid head in palmitic 
acid, and long C-H chain with conjugated diene moiety is mimicking the long aliphatic chain in 
palmitic acid. However, it is not clear whether hydrophilic head group or long chain tail that 
makes triacsin C a potent inhibitor. The general approach for designing triacsin C analogs are 
changing the unstable hydroxyl triazene head group to other bioactive groups and changing the 
length and number of double bond of the long alkyl chain. 
 
A small library of triacsin C analogs was designed as shown in Figure 1.5 based on these criteria. 
 
H
N
COOH
1-1
N
N S
O
O
1-2
H
N
COOH
1-3
H
N
COOH
1-4
OH
N
N
1-5
OH
N
COOH
N
N
1-6
OH
N
N
N
OH
N
COOH
1-7
H
N
N S
O
O
1-8
H
N
OH
1-9
H
N
OH
1-10
N
1-11
O
NH
O
O
N
1-12
O
NH
O
O
COOH
 
Figure 1.5. Chemical structures of designed triacsin C analogs. 
 
Predicted log P values of the designed small molecules were calculated using interactive log P 
calculator (© Molinspiration Cheminformatics 2017)
24
, which is available online. The calculated 
results were shown in Table 1.1. Most of the designed molecules have the predicted log P values 
7 
less than five, which follows Lipinski rules. Some of the molecules (compounds 1-3, 1-4 and 1-
5) have predicted log P values as high as 6, meaning that they were supposed to be more 
hydrophilic and may cause some cell penetration and absorption problems later. Structural 
optimizations towards increasing hydrophobicity will be performed in the future to solve the 
problem to optimize the pharmacokinetics (PK) properties. 
 
Compound Chemical Structure 
Molecular 
Weight 
log P value 
1-1 
H
N
COOH  
285.39 5.21 
1-2 
N
N S
O
O
 
282.41 3.19 
1-3 
H
N
COOH  
289.42 6.16 
1-4 
H
N
COOH
OH
 
305.42 6.16 
1-5 
N
N
OH
N
COOH  
333.436 6.21 
1-6 
N
N
OH
N
COOH  
329.40 5.26 
1-7 
N
N
OH
N
COOH  
303.36 4.74 
1-8 
H
N
N S
O
O
 
284.43 3.11 
1-9 
H
N
OH  
185.31 4.24 
1-10 
H
N
OH  
181.28 3.28 
8 
1-11 
N
O
NH
O
O
 
254.33 3.31 
1-12 
N
O
NH
O
O
 
250.30 2.35 
Triacsin C N N
N
OH  207.28 3.21 
Palmitic acid 
O
OH  
256.43 7.06 
Table 1.1. Molecular weights and log P values of designed triacsin C analogs. 
 
 1.3.3 Synthetic routes 
The synthetic work was collaborated with Dr. Allan M. Prior in Hua group and I carried out the 
syntheses of compounds 1-2, 1-6, 1-7, 1-8, 1-10 and 1-12. The synthetic routes were shown as 
follows (Scheme 1.2 - Scheme 1.5). Compound (E,E,E)-2,4,7-undecatrien-1-al (1-13) was 
allowed to react with various nucleophiles to give designed molecules. The synthesis of aldehyde 
1-13 was followed by the reported procedure
15,18
 and shown in Scheme 1.2. Commercial 
available trans-2-hexen-1-ol (1-13-1) was brominated and displaced to give THP protected 
compound 1-13-2, which further deprotected with oxalic acid and underwent a series of 
reduction, oxidation and carbon extension reactions to give aldehyde 1-13. 
OH
a) PBr3, CH2Cl2
b) THPO-CH2-C CMgBr
yield: 96%
yield: 64%
OTHP
1-13-1 1-13-2
a)oxalic acid, MeOH
yield: 92%
b)LiAlH4, Et2O
yield: 88%
OH
1-13-3
IBX, DMSO
yield: 57%
H
O
(EtO)2POCH2CO2Et,
NaH, toluene
yield: 33% O
OEt LiAlH4; Et2O
yield: 88%
OH
IBX, DMSO
yield: 88%
H
O
1-13-4 1-13-5
1-13-6
1-13  
Scheme 1.2. Synthesis of compound 1-13. 
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Syntheses of compounds 1-2 and 1-8 were shown in Scheme 1.3. The intermediate aldehyde 1-
13 went through reductive amination and cyclization to give compound 1-2. Compound 1-2 was 
further reduced by NaCNBH3 to give compound 1-8. 
H
O
1-13
H2NNHSO2(CH2)3Cl, EtOH
yield: 52%
N
1-14
N
H
S Cl
OO
NaH, DMF
yield: 71%
N
N S
O
O
1-2
NaCNBH3, MeOH
yield: 53%
1-8
H
N
N
S
O
O
 
Scheme 1.3. Syntheses of compounds 1-2 and 1-8. 
 
Synthesis of compounds 1-6, 1-10 and 1-12 were shown in Scheme 1.4. The intermediate 
aldehyde 1-13 underwent reductive amination with hydroxylamine and the formed imine was 
further reduced by NaCNBH3 to give compound 1-10. The hydroxyl group in compound 1-10 
was displaced by isocyanate followed by cyclization under basic conditions to give compound 1-
12. Hydroxyl amine 1-10 was treated with p-diazonium benzoic acid to give compound 1-6. 
H
O
1-13
a) H2NOH
. HCl
NaOAc, EtOH
yield: 100%
b) NaCNBH3, MeOH
yield: 92%
H
N
1-10
OH
a) O C N CO2Et, CH2Cl2
yield: 69%
b) 3 N NaOH, dioxane
yield: 70%
N
1-12
O
NH
O
OH
N
1-10
OH
H
N
1-10
OH
COOHN2Cl
NaOAc, MeOH, 0 oC
yield: 48%
N
N
1-6
OH
N
COOH
 
Scheme 1.4. Syntheses of compounds 1-6, 1-10 and 1-12. 
 
Similar to the synthesis of compound 1-6, compound 1-7 was obtained from a different aldehyde 
(compound 1-13-4) as shown in Scheme 1.5. 
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N
N
OH
N
COOH
1-7
O
1-13-4
a) H2NOH
. HCl
NaOAc, EtOH
yield: 91%
b) NaCNBH3, MeOH
yield: 30%
1-14
H
N
OH
COOHN2Cl
NaOAc, MeOH, 0 oC
yield: 42%
 
Scheme 1.5. Synthesis of compound 1-7. 
 
 1.4 Bio-evaluaion  
Bio-evaluations were done by our collaborators. The in vitro and in situ ACSL inhibition tests 
were carried out by the Weis group in the Biomedical Sciences Department, Texas Tech 
University. Inhibition of leukocyte recruitment was conducted by Hung Pham, Qian Chen and 
Lindon H. Young in the Department of Pathology, Philadelphia College of Osteopathic 
Medicine. (Description of bio-methods was adapted with permission from supporting 
information of Prior et. al
25
 Bioorganic & Medicinal Chemistry Letters 2014, 24, 1057-1061. 
Copyright © 2014 Elsevier Ltd. License #4077240598278) 
 
All of the synthesized triacsin C analogs (compounds1-1 to 1-12) were screened for ACSL 
inhibition in vitro. Selected compounds (1-1, 1-2, 1-3, 1-4, 1-7 and 1-9) were tested further for 
ACSL inhibition in situ. Finally, compounds 1-1 and 1-9 were tested in vivo for inhibition of 
leukocyte recruitment. 
 
 1.4.1 Methods 
 1.4.1.1 The in vitro ACSL inhibition 
The activities of compounds 1-1 through 1-12 to inhibit ACSL were measured in an in vitro 
assay. Immortalized mouse brain endothelial cells (bEND3 cells) were grown to confluence in 
11 
25cm
2
 tissue culture flasks. Confluent cultures were rinsed three times with ice-cold calcium and 
magnesium free phosphate buffered saline (CMFPBS), then dissolved in 0.5 mL solubilization 
buffer. The solubilized cells were assayed immediately for FACS activity as described.
26
 Briefly, 
50 µL of solubilized cells were added to 100 µL of ACSL assay cocktail containing the 
appropriate concentration of triacsin C or analog. The reaction was allowed to proceed for 2 
minutes and terminated by the addition of 1.5 mL stop solution (isopropanol:n-heptane; 2M 
H2SO4, 40:10:1). Unreacted substrate was removed by adding 1.5 mL n-heptane and 1 mL DI 
H2O followed by vigorous vortexing. The organic layer was discarded and the aqueous layer was 
re-extracted twice with 2 mL n-heptane containing 4 mg/mL palmitic acid. The radioactivity in 1 
mL of the final aqueous layer was determined by liquid scintillation spectrometry.  
 
ACSL activity was normalized to the control (no drug) activity, and IC50 values were calculated 
using the constrained three-parameter log (inhibitor) vs. response function of the Prism 6.0 
statistical analysis package.  
 
A general in vitro ACSL inhibition test procedure was summarized in Figure 1.6. 
 
Figure 1.6. General procedure for in vitro ACSL inhibition test (conducted in Dr. Weis 
group). 
 
 1.4.1.2 The in situ ACSL inhibition 
Compounds 1-1, 1-2, 1-3, 1-4, 1-7 and 1-9 were tested in situ for the ability to inhibit [
14
C]-
palmitic acid incorporation into extractable lipids. The bEND3 cells were grown to confluence in 
6-well cluster plates. Confluent cultures were treated with Dulbecco’s Minimal Essential Media 
(DMEM), supplemented as described, and containing [
14
C]-palmitic acid (50 mC/mmol, a final 
12 
palmitate concentration of about 20 µM) plus the appropriate test compound at the 
concentrations indicated
26
. The medium contained about 7.4 mg/mL protein, from the fetal calf 
serum. After 2 hours, the plates were placed in an ice bath, and the media aspirated. The cells 
were rinsed 3 times with ice-cold CMFPBS, then scraped into 0.5 mL ice-cold CMFPBS and 
transferred to a glass screw-top tube. Each well was rinsed with an additional 0.5 mL ice-cold 
CMFPBS, followed by 0.8 mL ice-cold imidazole buffer. The rinses were pooled with the cells 
and lipids were extracted as described.
27,28
 The organic layers were collected in a pre-weighed 
glass vial, and the total extracted lipid weights were calculated. Radioactivity in both the lipid 
extract and the aqueous layer were determined by liquid scintillation spectroscopy.  
 
Results were expressed as moles of [
14
C]-palmitic acid incorporated per µg lipid. Incorporation 
in the presence of each inhibitor was compared to that in the control (vehicle) cells. Statistical 
significance was calculated by one-way analysis of variance, using the Prism 6.0 software 
package. 
 
A general in situ ACSL inhibition test procedure was summarized in Figure 1.7. 
 
Figure 1.7. General procedure for in situ ACSL inhibition test (conducted in Dr. Weis 
group). 
 
 1.4.1.3 Inhibition of leukocyte recruitment 
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The effect of compounds 1-1 and 1-9 on leukocyte rolling, adhesion and extravasation were 
evaluated in male Sprague Dawley rats (275 - 325 g; Ace Animals, Boyertown, PA), as 
described previously.
16
 A loop of the iliac mesentery was exteriorized and positioned in a 
Plexiglas chamber for visualization, then superfused with Krebs-Hensleit buffer (KHB). 
Leukocyte recruitment was initiated by adding 50 µM L-NAME to the KHB,
29
 in the presence or 
absence of test compound. Leukocyte recruitment in unbranched post-capillary venules (mean 
diameter 20 ± 0.3 μm) was captured on high-resolution video recordings. The numbers of rolling 
(moving at a velocity substantially slower than that of red blood cells), adherent (firmly attached 
to the vascular endothelium for > 30 seconds) and transmigrated (in the tissue adjacent to the 
post-capillary venules) leukocytes were determined during playback analysis of the recorded 
images. Statistical significance for each parameter was calculated by analysis of variance for 
repeated measures, using the Prism 6.0 software package.  
 
The Institutional Animal Care and Use Committee of the Philadelphia College of Osteopathic 
Medicine approved this study. 
 
 1.4.2 Results  
 1.4.2.1 The in vitro ACSL inhibitory activity 
All of the synthesized small molecules (compounds 1-1 to 1-12) were screened for their in vitro 
ACSL inhibitory activity in solubilized brain endothelial bEND3 cells together with triacsin C. 
 
The results were shown in Table 1.2 and Figure 1.8. Except compound 1-2 and compound 1-8, 
all of the other ten compounds showed moderate to good ACSL inhibitory ability with median 
effective concentration (EC50) values ranging from 4.95 to 74.8 μM. Among the ten active 
analogs, compounds 1-1 (EC50 = 5.86 μM) and 1-3 (EC50 = 4.95 μM) were found to be lead 
compounds with micromolar range efficacy. Although they are 10 times less active than triacsin 
C, which has nanomolar range efficacy, they could act as a good starting point towards the 
development of more potent inhibitors through further structural optimization. 
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Compound EC50 (µM) Compound EC50 (µM) 
1-1 5.86 ± 0.54 1-7 26.9 ± 3.6 
1-2 171 ± 79.0 1-8 164 ± 60.8 
1-3 4.95 ± 0.74 1-9 70.4 ± 14.0 
1-4 6.88 ± 0.66 1-10 14.8 ± 1.6 
1-5 73.1 ± 9.6 1-11 9.04 ± 1.45 
1-6 74.8 ± 34.8 1-12 53.5 ± 33.2 
Triacsin C 0.358 ± 0.027   
Table 1.2. ACSL inhibition in solubilized brain endothelial bEND3 cells. The EC50 values 
were calculated by fitting the velocity versus inhibitor concentration to the constrained three-
parameter log (inhibitor) versus response fuction of the Prism 6.0 statistical snalysis package. 
(This table was adapted with permission from Prior et. al
25
 Bioorganic & Medicinal Chemistry 
Letters 2014, 24, 1057-1061. Copyright © 2014 Elsevier Ltd. License #4077240598278) 
 
 
Figure 1.8. Concentration effect curves of the inhibition of ACSL activity in solubilized 
brain endothelial bEND3 cells for each of the analogs, as compared to triacsin C. (This 
figure was adapted with permission from Prior et. al
25
 Bioorganic & Medicinal Chemistry Letters 
2014, 24, 1057-1061. Copyright © 2014 Elsevier Ltd. License #4077240598278) 
 
 1.4.2.2 The in situ ACSL inhibitory activity 
Compounds 1-1, 1-2, 1-3, 1-4, 1-7 and 1-9 were tested for their in situ ACSL inhibition using 
[
14
C]-palmitic acid. Data were calculated by analyzing the radioactivities in the recovered media 
and aqueous layer and organic layer after extraction. The in situ ACSL inhibition results were 
shown in Figure 1.9. 
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Figure 1.9. The in situ inhibition of ACSL by triacsin C and analogs in bEND3 brain cells, 
as evaluated by the incorporation of [
14
C]-palmitic acid into extractable lipid (A), aqueous 
(B), media (C), and recovery (D). Triacsin C was used at 1.5 μM, while all other compounds 
were evaluated at 15 μM. Differences between the treatment groups and control were evaluated 
by one-way ANOVA, followed by Dunnett’s t test for significance. * = p < 0.05; ** = p < 0.01; 
*** = p < 0.001; **** = p < 0.0001. n= 3-9 independent experiments. (This figure was adapted 
with permission from Prior et. al
25
 Bioorganic & Medicinal Chemistry Letters 2014, 24, 1057-
1061. Copyright © 2014 Elsevier Ltd. License #4077240598278) 
 
As shown in Figure 1.9 (A), in the presence of ACSL inhibitors, the radioactivity of lipid layer 
all apparently decreased except compounds 1-2 and 1-7 in the lipid. The decreased radioactivity 
is due to the reduced amount of [
14
C]-palmitate in the lipid. In other words, ACSL function in the 
cell was inhibited and led to less formation of [
14
C]-palmitate, which entered the organic layer 
after extraction. Figure 1.9 (B) showed the efficiency of aqueous extraction. Except compound 1-
2, all other compounds possess less than 0.7% of the total radioactivity in the aqueous layer, 
which means through extraction, most [
14
C]-palmitate entered the organic layer. In Figure 1.9 
(C), all compounds have over 100% radioactivity than control sample, because more unreacted 
[
14
C]-palmictic acid was left behind inside the media due to the inhibition of in situ ACSL 
activity. Figure 1.9 (D) indicated that the total recovery of radioactivity are almost same. This 
excluded the possibility that the reduction of lipid layer recovered radioactivity was due to 
16 
decomposition of [
14
C]-palmitic acid. The constant total recovery verified that reduced [
14
C]-
palmitate amount is the main reason for the radioactivity loss in lipid, in other words, inhibition 
of ACSL activity did occur in the cell treated with synthesized small molecules.  
 
 1.4.2.3 Leukocyte recruitment inhibition 
Compounds 1-1 and 1-9 were further tested for their leukocyte recruitment inhibition and results 
were shown in Figure 1.10. 
 
 
Figure 1.10. The L-NAME induced leukocyte recruitment at 120 minutes in the presence of 
compounds 1-1 and 1-9. Rolling, adhesion and extravasation were measured in post-
capillary venules of the mesentery, a model of ischemia, and in the presence or absence of 5 
or 50 µM compound 1-1 or 50 µM compound 1-9. The rolling, adhesion and extravasation 
rates for 50 µM compound 1-1 and 5 µM triacsin C were not different from each other nor were 
they different from vehicle alone. When evaluated at 5 µM, compound 1-1 inhibited the 
recruitment to about half the extent as at 50 µm.  Compound 1-9 at 50 µM was about as effective 
as compound 1-1 at 5 µM.  Each bar represents the mean ± SEM of 3 to 7 independent 
experiments. (This figure was adapted with permission from Prior et. al
25
 Bioorganic & 
Medicinal Chemistry Letters 2014, 24, 1057-1061. Copyright © 2014 Elsevier Ltd. License 
#4077240598278) 
 
Figure 1.10 suggested that compounds 1-1 and 1-9 could inhibit the L-NAME induced leukocyte 
rolling, adhesion and extravasation. Compound 1-1 is more potent than 1-9 in leukocyte 
recruitment inhibition. Although compound 1-1 is still 10 times less effective than triacsin C, but 
it could act as a good start point. Compared with triacsin C, compound 1-1 is still a competitive 
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lead compound with much easier synthetic routes. And through further structural optimization, it 
could lead to the discovery of more efficient inhibitors. 
  
 1.4.3 Discussion 
 1.4.3.1 Structure-activity relationship of the synthesized triacsin C analogs towards 
in vitro ACSL inhibitory ability 
Changes in structural moieties which may have an effect on in vitro ACSL inhibitory 
activity: 
Entry 1. Head group  
 4-amino benzoic acid: 1-1, 1-3, 1-4 
H
N
COOH
1-1
H
N
COOH
1-3
H
N
COOH
1-4
OH
(EC50 = 5.86 uM) (EC50 = 4.95 uM)
(EC50 = 6.88 uM)
 
 4-diazenylbenzoic acid: 1-5, 1-6,1-7 
N
N
1-5
OH
N
COOH
N
N
1-6
OH
N N
N
OH
N
COOH
1-7
COOH
(EC50 = 73.1  uM) (EC50 = 74.8   uM) (EC50 = 26.9  uM)
 
 1,2,4 oxadiazolidine-3,5-dione : 1-11, 1-12 
N
1-11
O
NH
O
O
N
1-12
O
NH
O
O
(EC50 = 9.04 uM) (EC50 = 53.5 uM)  
 isothiazolidine dioxides 1-2, 1-8 
N
N S
O
O
1-2
H
N
N S
O
O
1-8(EC50 = 171 uM) (EC50 = 164 uM)  
 
Entry 2. H-bond donor in head group: 1-1 Vs 1-4 
 
H
N
COOH
1-1
H
N
COOH
1-4
OH
(EC50 = 5.86 uM)
(EC50 = 6.88 uM)
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Entry 3. Length of aliphatic chain: 1-6 Vs 1-7 
N
N
1-6
OH
N N
N
OH
N
COOH
1-7
COOH
(EC50 = 74.8   uM) (EC50 = 26.9  uM)  
Entry 4. Conjugated diene moiety: 
 1-1 Vs 1-3                                                          1-5 Vs1-6 
H
N
COOH
1-1
H
N
COOH
1-3
(EC50 = 5.86 uM)
(EC50 = 4.95 uM)
N
N
1-5
OH
N
COOH
N
N
1-6
OH
N
COOH
(EC50 = 73.1  uM)
(EC50 = 74.8   uM)
 
Entry 5. Acidic head group: 1-10, 1-9 Vs triacsin C 
H
N
OH
1-9 (EC50 = 70.4 uM)
H
N
OH
1-10 (EC50 = 14.8 uM)
N
N
N
OH
Triacsin C (EC50 = 0.358 uM)  
Table 1.3. Structure-activity relationship of triacsin C analogs towards ACSL inhibitory 
ability (in vitro). 
 
The isothiazolidine dioxides structural moiety (Entry 1, compounds 1-2 and 1-8) turned out not 
to be a good head group. The p-amino benzoic acid was the most active head group (Entry 1, 
compounds 1-1, 1-3, 1-4), however, adding a N=N bond between the amine and benzoic acid 
greatly decreased activity (Entry 1, compounds 1-5, 1-6, 1-7). Introducing hydrogen bond 
donating group in the head group phenyl ring does not increase its activity (Entry 2, compound 
1-4). The conjugated diene moiety is not necessary for effectiveness (Entry 4, compounds 1-1 
and 1-3). Changing head group to more acidic 1,2,4 oxadiazolidine-3,5-dione does not improve 
efficiency (Entry 1, compounds 1-11 and 1-12). The lack of the hydrophilic head group will lead 
to a decrease of activity (Entry 5, compounds 1-9 and 1-10). 
 
In summary, acidic head group structural moiety is needed when designing triacsin C analogs 
while conjugated diene structural moiety in the long aliphatic chain does not play so significant 
roles in potency. 
 
 1.4.3.2 Concerns 
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Triacsin C is believed to inhibit ACSL activity by blocking the substrate binding site.
13
 Our 
analogs are supposed to work in the same way. However, there is no evidence that which kind of 
interaction between the inhibitors and substrate binding site plays an important role. Further 
computational docking can be applied to illustrate the binding mode. Triacsin C is a nonspecific 
inhibitor, structural modification on triacsin C analogs towards improving their sub-type 
selectivity among different ACSL isomers could be explored in the future. So far only inhibition 
of leukocyte recruitment is done as the indicator for reducing I/R injury. Later, more experiments 
can be done to discovery more direct evidence of attenuation of I/R injury such as reduced size 
of infarction. 
 1.5 Conclusion 
A small library of triacsin C analogs were designed and synthesized. Straight forward synthetic 
routes were developed and most steps are with moderate to good yield. ACSL inhibition tests 
showed promising results on the discovery of active triacsin C analogs as ACSL inhibitors. All 
of the designed triacsin C analogs inhibit ACSL activity except compounds 1-2 and 1-8. 
Compounds 1-1 and 1-3 have the greatest activity with EC50 values of 5.86 and 4.95 µM, 
respectively. Structure-activity relationship was discussed based on the ACSL inhibition results. 
Results of inhibition of leukocyte recruitment indicated that inhibiting ACSL could attenuate I/R 
injury which is associated with vascular inflammatory. 
 
 1.6 Synthetic experimental procedures 
 1.6.1 General 
Chemicals were purchased from Fisher Scientific and VWR international LLC. NMR spectra 
were taken from a 400 MHz Spectrometer (Varian Inc.) in chloroform-D unless otherwise 
informed. Mass spectra were obtained from an API 2000-triple quadrupole ESI-MS/MS mass 
spectrometer (Applied Biosystems). Compounds 1-13 and 1-2 were synthesized following 
reported procedures
15,18
 and characterized by 
1
H NMR and MS, and the spectra are identical to 
those reported.  
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 1.6.2 Representative synthesis 
 1.6.2.1 (2E,4E,7E)-N-Undeca-2,4,7-trienylhydroxylamine (Compound 1-10). 
H
N
1-10
OH
 
To a solution of hydroxylamine hydrochloride (0.61 mmol) and sodium acetate (0.61 mmol) in 
0.2 mL of water was added a solution of aldehyde 1-13 (0.12 mmol) in 2 mL of EtOH. After 
stirring at 25
o
C for 2 h, the reaction solution was diluted with water and extracted twice with 
CH2Cl2. The combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated to yield 22 mg (100% yield) of the oxime intermediate as an oil. To a solution of 
oxime intermediate (0.22 mmol) and 80 L of 3 N HCl in 2 mL of MeOH, was added NaCNBH3 
(0.6 mmol) in two portions, and stirred at 25
o
C for 3 days. The reaction was diluted with water 
and extracted three times with CH2Cl2. The combined organic layers were washed with brine, 
dried over MgSO4, filtered and concentrated to give 37 mg (92% yield) of compound 1-10 as a 
solid. 
1
H NMR  ppm 6.23 (dd, J = 14.9, 10.5 Hz, 1H), 6.05 (dd, J = 14.9, 11.2 Hz, 1H), 5.60 - 
5.73 (m, 2H), 5.35 - 5.49 (m, 2H), 3.56 (d, J = 6.6 Hz, 2H), 2.77 (t, J = 5.7 Hz, 2H), 1.93 - 2.01 
(m, 2H), 1.32 - 1.44 (m, 2H), 0.85 - 0.93 (m, 3H). 13C NMR  ppm 134.3, 133.6, 131.7, 129.9, 
127.5, 126.1, 55.83, 35.5, 34.7, 22.6, 13.7.  MS (positive mode), m/z calcd for  C11H20NO 
(M+H)
+
 182.2, found 182.1. 
 1.6.2.2 N-((4-Hydroxycarbonyl)pheynlazo)-N-(2E,4E,7E)-(undeca-2,4,7-trienyl) 
hydroxylamine (Compound 1-6) 
N
N
1-6
OH
N
COOH
 
To a cold (0
o
C) solution of hydroxylamine 1-10 (83 mol) in 1 mL of MeOH was added 
dropwise an aqueous solution of 4-(hydroxycarbonyl)phenyldiazonium chloride (0.083 mmol) 
and sodium acetate (0.50 mmol) in 1 mL of water concurrently. After stirring at 0
o
C for 20 min 
the reaction was diluted with diethyl ether and water, acidified with acetic acid to pH = 4. The 
21 
organic layer was washed twice with water, brine, dried over NaSO4, filtered, concentrated, and 
column chromatographed on silica gel using a mixture of diethyl ether and hexane (1:1) as eluent 
to yield 13 mg (48% yield) of compound 1-6 as a solid. 
1
H NMR  ppm 10.27 (s, 1H), 8.06 (d, J 
= 8.6 Hz, 2H), 7.17 (d, J = 8.6 Hz, 2H), 6.41 (dd, J = 15.5, 11.3 Hz, 1H), 6.08 (dd, J = 15.5, 10.7 
Hz, 1H) 5.77 - 5.87 (m, 2H), 5.33 - 5.49 (m, 2H), 4.74 (d, J = 7.0 Hz, 2H), 2.80 (t, J = 6.3 Hz, 
2H), 1.93 - 2.02 (m, 2H), 1.32 - 1.43 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H). 
13
C NMR  ppm 171.3, 
144.5, 137.7, 136.7, 132.4, 130.4, 129.2, 127.3, 123.3, 120.5, 113.9, 66.0, 35.8, 34.9, 22.8, 13.9.  
MS (negative mode), m/z calcd for  C18H22N3O3 (M-H)
-
 328.2, found 328.3. 
 1.6.2.3 2-((2E,4E,7E)-Undeca-2,4,7-trienylamino)-1,1-dioxo-1-isothiazolidine 
(Compound 1-8) 
1-8
H
N
N
S
O
O
 
To a solution of 8 mg (28 mol) of compound 1-2 in 3 mL of methanol was added 9 mg (0.14 
mmol) NaCNBH3 followed by 2 drops of 3 M HCl in methanol. The solution was stirred at 25
o
C 
for 45 min., diluted with aqueous NaHCO3 solution, and extracted with CH2Cl2 twice. Combined 
organic layers were washed with brine, dried over MgSO4, fitered, concentrated and column 
chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as eluent to 
give 4.2 mg (53% yield) of compound 1-8. 
1
H NMR  ppm 6.22 (dd, J = 15.0, 10.0 Hz, 1H), 
6.05 (dd, J = 15.0, 10.0 Hz, 1H), 5.71 (dt, J = 15.0, 7.0 Hz, 1H), 5.62 (dt, J = 15.0, 7.0 Hz, 1H), 
5.49 – 5.36 (m, 2 H), 4.22 (bs, 1H, NH), 3.82 (d, J = 7.0 Hz, 2 H, CH2N), 3.168 (dd, J = 6.5, 6.3 
Hz, 2H), 3.08 (q, J = 5.0 Hz, 2H), 2.78 (t, J = 5.0 Hz, 2H), 2.31 (pent, J = 5.6 Hz, 2H), 1.98 (q, J 
= 7.6 Hz, 2H), 1.38 (sextet, J = 7.6 Hz, 2H), 0.90 (t, J = 7.6 Hz, 3H). 
13
C NMR  ppm 134.9, 
134.1, 131.8, 129.5, 127.4, 124.7, 49.6, 45.3, 35.6, 34.7, 29.7, 28.5, 22.6, 13.7. MS (positive 
mode), m/z calcd for C14H24N2NaO2S (M+Na)
+
 307.1, found 307.2. 
 1.6.2.4 2-((2E,4E,7E)-Undeca-2,4,7-trienyl)-(1,2,4)oxadiazolidine-3,5-dione 
(Compound 1-12) 
22 
N
1-12
O
NH
O
O
 
To a solution of hydroxylamine 1-10 (83 mol) in 1 mL of CH2Cl2 was added ethyl 
isocyanoformate (83 mol), and the solution was stirred at 25oC for 3 h. The reaction solution 
was diluted with water, and extracted with diethyl ether.  The organic layer was washed with 
brine, dried over MgSO4, filtered and concentrated to give 20 mg (69% yield) of the 
corresponding carbamate intermediate as an oil. To a solution of the above carbamate 
intermediate (0.057 mmol) in 3 mL of dioxane at 0
o
C was added dropwise 3 N NaOH (0.14 
mmol), and the solution was stirred at 25
o
C for 18 h. The reaction solution was diluted with 
water, acidified to pH = 4 using 2 N HCl, and extracted three times with ethyl acetate.  The 
combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated, 
and placed under high vacuum for 12 h to give 10 mg (70% yield) of compound 1-12 as an oil. 
1
H NMR  ppm 6.13 - 6.29 (m, 1H), 5.94 - 6.07 (m, 1H), 5.62 - 5.75 (m, 1H), 5.23 - 5.60 (m, 
3H), 4.16 - 4.30 (m, 2H), 2.65 - 2.84 (m, 2H), 1.92 - 2.05 (m, 2H), 1.27 - 1.41 (m, 2H), 0.83 - 
0.93 (m, 3H). 
13
C NMR  ppm 156.9, 151.8, 137.5, 136.41, 132.4, 129.1, 127.3, 120.6, 51.4, 
35.9, 35.0, 22.9, 14.0.  MS (negative mode), m/z calcd for C13H17N2O3 (M-H)
-
 249.1, found 
249.2. 
 1.6.2.5 N-((4-Hydroxycarbonyl)phenylazo)-N-(nona-2E,5E-dienyl) hydroxylamine 
(Compound 1-7) 
N
N
OH
N
COOH
1-7  
To a solution of hydroxylamine hydrochloride (3.62 mmol) and sodium acetate (3.62 mmol) in 
1.2 mL of water was added a solution of 2E,5E-nonadienal (compound 1-13-4, 0.73 mmol) in 10 
mL of EtOH and the resulting solution was stirred at 25
o
C for 2 h. The solution was diluted with 
water and extracted three times with dichloromethane. The combined organic layers were 
washed with brine, dried over MgSO4, filtered and concentrated to give 0.10 g (91% yield) of the 
corresponding oxime intermediate as an oil. To a solution of the above oxime (0.65 mmol) and 
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0.24 mL of 3 N HCl in 5 mL of MeOH was added NaCNBH3 (1.7 mmol) in portions, and stirred 
at 25
o
C for 18 h. The reaction solution was diluted with water, basified to pH = 10 using 3 N 
NaOH, and extracted three times with CH2Cl2. The combined organic layers were washed with 
brine, dried over MgSO4, filtered, and concentrated to yield 30 mg (30% yield) of 
hydroxylamine 1-14. To a cold (0
o
C) solution of hydroxylamine 1-14 (0.19 mmol) in 1 mL of 
MeOH was added dropwise an aqueous solution of 4-(hydroxycarbonyl)phenyldiazonium 
chloride (0.19 mmol) and aqueous sodium acetate (1.2 mmol) concurrently.  The solid precipitate 
was collected by filtration and washed three times with cold water, dried under vacuum to give 
25 mg (42% yield) of compound 1-7 as a solid. 
1
H NMR  ppm 10.27 (br. s., 1H), 8.06 (d, J = 
8.6 Hz, 2H), 7.16 (d, J = 8.6 Hz, 2H), 5.90 - 5.98 (m, 1H), 5.71 - 5.80 (m, 1H), 5.36 - 5.53 (m, 
2H), 4.69 (d, J = 6.6 Hz, 2H), 2.81 (t, J = 5.9 Hz, 2H), 1.92 - 2.03 (m, 2H), 1.33 - 1.42 (m, 2H), 
0.89 (t, J = 7.4 Hz, 3H). 
13
C NMR  ppm 170.4, 144.3, 137.9, 132.6, 132.1, 126.5, 120.7, 113.8, 
113.7, 65.8, 35.2, 34.6, 22.5, 13.7.  MS (negative mode), m/z calcd for C16H20N3O3 (M-H)
-
 
302.2, found 302.1. 
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Chapter 2 - Design, synthesis and bio-evaluation of 1,3,4-oxadiazole 
derivatives as T-type calcium channel inhibitors 
 2.1 Background and significance 
 2.1.1 T-type calcium channel  
Voltage-gated calcium channels (VGCCs) are transmembrane, multi-subunit proteins that 
modulate influx of calcium ion (Ca
2+
) into the cell in response to membrane depolarization. 
According to different activation potentials, generally VGCCs can be classified as high voltage-
activated (L-, N-, P-/Q- and R-types) and low voltage-activated (T-type).
1,2
 T-type calcium 
channels are characterized with transient and tiny Ca
2+
 currents and composed of five subunits 
(Figure 2.1). As shown in Figure 2.1, α1 is central pore-forming subunit and is the primary 
subunit while the others are called auxiliary subunits regulating channel properties.
1
 Among 
different auxiliary subunits, β is an intracellular subunit; α2 and δ subunits form a glycoprotein 
dimer and γ subunit is a transmembrane glycoprotein.2,3 Based on the differences between pore-
forming α1 subunit, T-type calcium channels are classified into three sub-types: Cav3.1 (α1G), 
Cav3.2 (α1H), and Cav3.3 (α1I).3-7 The three sub-types are heterogeneously expressed in the 
brain and organs such as the heart, vascular smooth muscle, non-vascular smooth muscle, 
skeletal muscle and others.
8-13
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Figure 2.1. T-type calcium channels (cartoon presentation) are multi-subunits protein 
complexes. 
 
Although T-type calcium currents were first discovered in 1975 by Hagiwara et al.
14
, until 
recently T-type calcium channels have drawn great attention with the discoveries of different 
genes encoding α1 subunits3-7. The opening of calcium channels leads to a Ca2+ influx, which 
increases both membrane depolarization and intracellular Ca
2+
 concentration. The changing in 
intracellular Ca
2+
 concentration has an effect on some important processes like muscle 
contraction
13
, electrical conduction, neurotransmission and others
3
. T-type calcium channels 
have been reported to be involved in the mechanisms of cell development, hormone secretion, 
epilepsy and others.
15
 
 
 2.1.2 Epilepsy and T-type calcium currents influx 
Seizure is defined as “disturbances in the electrical activity of the brain” and epilepsy is defined 
as “two or more unprovoked seizures separated by at least 24 hours”.16 Based on an epilepsy 
report
17
 published by Institute of Medicine (MOI) in 2012, there are 2.2 million people in the 
United States have epilepsy and around 150,000 new cases of epilepsy are diagnosed each year. 
Ranking right after migraine, stroke, and Alzheimer’s disease, epilepsy has become the 4th most 
frequently occurring neurological disease in the United States.
18
  
30 
 
Upon the exploration of epilepsy models, changes in the cellular Ca
2+
concentration have been 
found. Back to 1977, Heinemann et al.
19
 found that during the process of seizures, intracellular 
calcium concentration increased and extracellular calcium concentration decreased. This 
discovery led to a hypothesis that an increased calcium currents would result in epilepsy. Later, 
more research results were reported to support this hypothesis. In 1995, Tsakiridou et al.
20
 
studied absence epilepsy on rodent models and they found that increased T-type currents were 
first observed in select thalamic nuclei from genetic absence epileptic rats. However, there was 
no effect for the amplitude of L-type currents, indicating that epilepsy results from increasing T-
type currents. Thus, T-type calcium channels could be a good target for the treatment of epilepsy. 
Nowadays, although many T-type calcium channel inhibitors have been reported,
21-23
 only small 
amount of the reported inhibitors could have a chance to enter clinical trial. Most of them are 
failed in the pre-clinical studies. Discovery of more new T-type calcium channel inhibitors are 
still needed. 
 
 2.2 Research objectives 
Research objective 1: Design and synthesize small molecules as T-type calcium channel 
inhibitors. 
Research objective 2: Study the structure-activity relationship (SAR) of synthesized small 
molecules based on their inhibitory ability towards T-type calcium channels. (This biological 
study was performed in our collaborator, Dr. Ximin Simon Xie’s laboratory) 
Research Objective 3: Explore the relation between inhibition of T-type calcium channels and 
seizure. (This biological study was performed in our collaborator, Dr. Ximin Simon Xie’s 
laboratory) 
 
 2.3 Molecular design and synthetic routes 
 2.3.1 Reported T-type calcium channel blockers 
Some of the reported T-type calcium channel blockers were summarized in Figure 2.2 and most 
of them were covered by patents
21
. Mibefradril was a FDA approved anti-hypertension drug and 
put into market in 1997. It selectively inhibited T-type (IC50 = 0.1 μM) over L-type (IC50 = 3 
31 
μM) calcium channels24. However, later severe drug-drug interactions were discovered, and 
mibefradril was retracted from market in 1998.
25
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Figure 2.2. Reported T-type calcium channel blockers.
21,24,26-30
  
 
There are some common structural features shared by the reported blockers. All of them have at 
least one aromatic ring. All of them have at least one basic N atom. Most of them have amide 
bond in their structures. Most of them have flexible aliphatic linkers. The molecule is not planar. 
These common features are good guidance in the molecular design. 
 
 2.3.2 Oxadiazoles derivatives as T-type Ca2+ channel inhibitors 
1,3,4-Oxadiazole structural motif has played an important role in the field of drug discovery 
because that it has wide range of biological activities including anti-inflammatory, anticancer, 
antibacterial, and others.
31-33
 Oxadiazole compounds have been reported to act as L- and T-type 
calcium channel blockers.
29,30,34
 In 2011, Xiang et al
23
 conducted a T-type Calcium channel high 
throughput screen (HTS) among 110,720 compounds in MLSCN/MLPCN (Molecular Libraries 
Screening /Production Center Network) library. Through several different HTS screens as 
described in the reference
23
, finally, only 1 hit compound CID3373841 (Figure 2.3) was 
confirmed to selectively inhibit T-type calcium channel towards L- and N- type channels. Further 
32 
structural optimization lead to a more potent T-type calcium channel inhibitor CID46943243
23
 
(Figure 2.3), which suggested that 1,3,4-oxadiazole could be a good pharmacophore for the 
inhibition of T-type calcium channels. 
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Figure 2.3. Chemical structures of compound CID3373841 and compound CID46943243. 
 
 2.3.3 Molecular design 
A series of small molecules containing 1,3,4-oxadiazole core was designed as shown in Figure 
2.4. The 1,3,4-oxadizole core was kept in all proposed small molecules considering its efficacy-
necessary. Branches on both sides were replaced with various functional groups to achieve better 
bioactivities (Figure 2.4). Modifications in part A were focused on the substitution of different 
aromatic rings to adjust the molecular lipophilicity. Diverse functional groups were introduced in 
part B to explore the structural features which may have an effect on potency, such as rigidity, 
flexibility, planarity, aromaticity, steric hindrance and others. 
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Figure 2.4. Designed substituted 1,3,4-oxadiazole compounds as T-type calcium channel 
inhibitors. 
 
Predicted Log P values were calculated using interactive log P calculator (© Molinspiration 
Cheminformatics 2017)
35
, which is available online. The calculated results were shown in Table 
2.1. Except compound CI-6 with log P value slightly over 5, all other designed 1,3,4-oxadiazole 
derivatives have predicted log P values between 2 to 5, which follow the Lipinski rules. 
 
Compound Chemical Structure Molecular Weight log P value 
CI-1 
S
Cl
O
NN
N Cl
Cl
O
O  
400.62 5.06 
CI-2 
S
Cl
O
NN
N
H
O Cl
 
368.24 4.67 
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O
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O
 
305.74 3.41 
CI-4 
S
Cl
O
NN
N
H
O
N N
H
O
 
445.92 3.67 
CI-5 O
NN
N
H
O Cl
 
327.76 4.08 
CI-6 O
NN
N
H
O
S
Cl  
305.74 3.52 
CI-7 O
NN
N
 
229.28 2.94 
CI-8 
O
NN
N
H
O
N
 
286.33 2.42 
CI-9 
O
NN
N
H
O
N
CN
 
311.34 2.06 
CI-10 
O
NN
N
H
OF
S
Cl
 
323.73 3.64 
Table 2.1. Molecular weights and log P values of designed 1,3,4-oxadiazole derivatives. 
 
 2.3.4 Synthetic routes 
The synthetic work was collaborated with Ms. Medha J. Gunaratna, graduate student in Hua 
group and I carried out the syntheses of compounds CI-1, CI-2, CI-3, CI-4 and CI-6. The 
synthetic routes were shown as follows (Scheme 2.1 - Scheme 2.5). The synthesis of 1,3,4-
oxadiazole ring was followed by reported procedure (Scheme 2.1).
36
 Commercially available 
thiosemicarbazide (compound 2-1) coupled with different acyl chlorides, and the resulting amide 
intermediates (compounds 2-2 and 2-3) underwent cyclization reaction to give the 1,3,4-
oxadiazole rings (compounds 2-4 and 2-5). 
35 
Cl R1
O
H2N
S
H
N
N
H
O
R1
H2N
H
N
NH2
S
+
Ar, 0o C -> rt
overnight
THF
R1= SCl
R1=
yield :60%
yield: 100%
2-1 2-2, 2-3
2-2:
2-3:
H2N
S
H
N
N
H
O
R1
O
NN
NH2R1
1.1 equiv. DBDMH
N
N
O
Br
Br
O
0.3 equiv. KI, 1.5 equiv. NaOH
water, 0 oC -> rt, 4hr
R1= SCl
R1=
yield :49%
yield: 41%
2-2, 2-3
2-4, 2-5
2-4:
2-5:
THF: tetrahydrofuran
DBDMH: 1,3-dibromo-5,5-dimethylhydantoin
 
Scheme 2.1. Syntheses of compounds 2-4 and 2-5. 
 
Possible mechanism of cyclization was shown in Scheme 2.2
31,37
. KI was first oxidized by 
DBDMH to form I2. The acyl-substituted thiosemicarbazide (compound 2-a) was activated by 
the formed I2 followed by elimination, cyclization and finally produced the designed ring 
compound 2-e. 
36 
Step 1: DBDMH works as an effective oxidant oxidizing KI to I2.
N
N
O
Br
Br
O
2 KI + 2 H2O + I2  +  Br2 + HN
NH
O
O
+ 2 KOH
Step 2: Cyclization
Ar N
H
O
H
N
S
N
H
H
I I+
OH -
- I -
Ar N
H
O
N
S
NH- H2O
I OH 
-
H
- H2O
-S2-, - I-
Ar
O
N N C NH
H
OH -
NN
OAr
N H
H
O
H
- OH - NN
OAr
NH2
2-a 2-b 2-c
2-d 2-e  
Scheme 2.2. Possible mechanism of formation of 1,3,4-oxadiazole ring.
31,37
 
 
Syntheses of compounds CI-1, CI-2, CI-3 and CI-4 were shown in Scheme 2.3. Generally, 
amine 2-4 underwent replacement reactions with various acyl chorides under basic conditions to 
give designed amide compounds (CI-1, CI-2 and CI-3). One problem is that the reaction 
pathway was not efficient considering the low to moderate reaction yields. After finding the hit 
compounds, further reaction condition optimization is needed to improve the yield. One possible 
reason for the low reaction yield was poor solubility of amide 2-4. Compound 2-4 was not 
completely dissolved in dichloromethane. Changing solvents to N,N-dimethyl formamide (DMF) 
could be a way to improve the reaction yield. Slightly different from the syntheses of CI-1, CI-2 
and CI-4, compound CI-4 was synthesized through coupling reaction between amine 2-4 and 
carboxylic acid 2-6. Carboxylic acid is less electrophilic than acyl chloride, so coupling reagent 
EDC was used to activate the carboxylic acid group. 
37 
1.5 equiv. pyridine,CH2Cl2,
rt, 5hr S
Cl
O
NN
N
H
R2
O
CI-n
S
Cl
O
NN
NH2 + Cl R2
O
2-4
CI-1 :
CI-2 : R2 =
aCI-3 : R2 =
bCI-4 :  react with
yield : 22%
Cl yield: 64%
yield: 6%
N
COOH
O
H
N
 yield: 11%
a  1.5 equiv. pyridine, CH2Cl2, rt, overnight
b  3 equiv EDC, 3 equiv. DMAP, DMF, CH2Cl2,
     50 oC, overnight
EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
DMAP: 4-Dimethylaminopyridine
DMF: Dimethylformamide
S
Cl
O
NN
N Cl
Cl
O
O
2-6  
Scheme 2.3. Syntheses of compounds CI-1, CI-2, CI-3 and CI-4. 
 
Synthesis of compound 2-6 was shown in Scheme 2.4. The acyl chloride 2-6-2 underwent 
replacement reaction with 4-cyanopiperidine (compound 2-6-1) under basic conditions. The 
resulting cyanide 2-6-3 was further hydrolyzed using 3 N NaOH aqueous solution in methanol to 
produce corresponding carboxylic acid 2-6.  
N
H
CN
2-6-1
+
O
N
H
Cl
2-6-2
K2CO3, CH3CN
reflux, 8hr, 99%
N
CN
O
H
N
2-6-3
3N NaOH
MeOH
reflux, 8hr,100%
N
COOH
O
H
N
2-6  
Scheme 2.4. Synthesis of compound 2-6. 
 
Synthesis of compound CI-6 was shown in Scheme 2.5. 5-Chlorothiophene-2-carboxylic acid 
(compound 2-7) reacted with oxalyl chloride to give acyl chloride 2-8, which further underwent 
replacement reaction with amine 2-5 under basic conditions to produce compound CI-6. 
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SHO
O
Cl
1.5 equiv.
Cl
Cl
O
O
DMF (cat.), CH2Cl2, 0 
oC->rt
2hr, 100 %
SCl
O
Cl
 1 equiv.
N
O
N
NH2
1.5 equiv. pyridine, CH2Cl2
   rt, 3.5 hr
N
O
N
N
H
O
S
Cl
CI-6
yield : 53%
2-5
2-7 2-8
 
Scheme 2.5. Synthesis of compound CI-6. 
 
 2.4 Bio-evaluation 
Bio-evaluation was performed by our collaborators Dr. Bende Zou, Dr. Christopher A. Lieu and 
Dr. Conrado Pascual in Dr. 
 
Xinmin (Simon) Xie’s laboratory at AfaSci Research Laboratory in 
Redwood City, California. 
 
 2.4.1 Methods 
 2.4.1.1 Patch clamp recordings 
Patch clamp recordings experiments were performed following reported procedure
38
 
(Description of the patch clam recording method was reprinted with permission from Jianyu Lu 
et al.
38
 Bioorganic & Medicinal Chemistry 2015, 23, 5985-5998. Copyright © 2015 Elsevier Ltd. 
License #4073710444987) and the mouse dorsal root ganglion (DRG) was prepared following 
reported procedure
38
. 
 
Whole-cell voltage clamp recordings were performed on large size (30-50 μM in diameter) 
mouse dorsal root ganglion (DRG) neurons within 2 days after acutely dissociation. All 
experiments were performed at room temperature (around 21
o
C). Whole-cell currents were 
recorded using a MultiClamp 700B amplifier and analyzed offline with pClAMP10.4 software 
(Axon CNS, Molecular Devices, formerly Axon Instruments). To record calcium currents, the 
external solution was composed of (in mM) 115 choline-Cl, 30 TEA-Cl, 2 CaCl2, 10 glucose and 
10 HEPES (pH 7.30-7.4 adjusted with TEA-OH and osmolality verified as 295 mOsm/kg). The 
internal solution was composed of (in mM) 125 CsCl, 10 HEPES (acid), 10 EGTA, 2 CaCl2, 1 
MgCl2, 4 MgATP and 0.3 MgGTP (pH 7.3-7.4 adjusted with CsOH, and the osmolality verified 
as 295 mOsm/kg). Since sodium component was removed in the external solution, TTX was not 
39 
needed. To record sodium currents, the external solution was remained as modified Kreb’s 
solution specified above. The internal solution was composed of (in mM) 120 CsF, 10 HEPES, 
11 EGTA, 1 CaCl2, 1 MgCl2, 10 TEA-Cl, 4 MgATP and 0.3 MgGTP (pH 7.3-7.4 adjusted with 
CsOH). In this recording condition, no obvious calcium components were observed in most cells. 
Occasionally, some L-type calcium components were observed but completely decayed quickly, 
perhaps due to high concentration of sodium component in the external solution. To record 
potassium currents, the external solution was remained as a modified Kreb’s solution specified 
above. The internal solution was composed of (in mM) 65 KCl, 80 KF, 5 KOH, 10 EGTA, 2 
MgATP (pH 7.350-7.4 adjusted with KOH). Recording electrodes were pulled by P-87 puller 
(Sutter Instrument Co.). The tip of resistance was 3–4 MΩ in bath and the series resistance was 
less than 10 MΩ after whole cell configuration. All compounds were purchased from Sigma 
unless specifically remarked. Drugs were bath applied to 1.5 mL external solution in the 
recording chamber and the final concentration was calculated as an even diffusion system. 
 
 2.4.1.2 Seizure models 
Seizure models were induced by pentylenetetrazole [40 mg/kg, intraperitoneal (i.p.) route] or 
maximal electronic shocks in mice following reported in vivo pharmacology assays
39
. 
Oxadiazole molecules were administered at 30 mg/kg concentration (i.p.). 
 
in vivo Pharmacology Assays(The description of methods was adapted with permission from 
Kristian Kaufmannet al
39
, ACS Chemical Neuroscience 2013, 4, 1278-1286. Copyright © 2013 
American Chemical Society.) 
  
For the pentylenetetrazole (PTZ)-induced seizure model, male mice (C57/BL6, 8-10 months old, 
approximately 30 g) were injected intraperitoneally with either compounds CI-2 and CI-6 (30 
mg/kg), sodium valproate (150 mg/kg), or vehicle (2% DMSO in 0.5% aqueous hydroxypropyl 
cellulose). After 30 min, PTZ was administered intraperitoneally (40 mg/kg). Immediately 
following administration of PTZ, the amount of time elapsed until the onset of convulsions, and 
death was recorded. If a mouse did not die after 20 min post-PTZ, the mouse was euthanized by 
isoflurane inhalation. The average convulsion latencies (in minutes) and the fatality rates of the 
40 
CI-2 and CI-6 group, the sodium valproate group, and the vehicle group were compared (n = 8 
mice/group). 
 
For the maximal electroshock seizure (MES) model, male, C57/BL6 mice (8-10 months old, 
approximately 30 g), were injected intraperitoneally with either compounds CI-2 and CI-6 (30 
mg/kg), sodium valproate (150 mg/kg) or vehicle. MES stimulation was applied, 30 min after 
injection, through trans auricular (ear-clip) electrodes from an electroshock apparatus, HSE 
Shock Stimulator Type 221, (Harvard Apparatus, Holliston, MA) using the following 
parameters: 100 mA fixed current, a 50-60 Hz pulse frequency, a 0.6 ms pulse width, and a 0.3 s 
stimulus duration. Animals were restrained by hand when applying the electrodes and released at 
the moment of stimulation to permit observation of the seizure throughout its entire course. Upon 
completion of the electrical stimulus, the time to onset of seizures was recorded. A 10 min cutoff 
was applied to all mice after which time the mice were euthanized by isoflurane inhalation. In 
this modified MES test, the electrical stimulus that was applied was sufficient to induce seizures 
and death from maximal seizure in 100% of the mice. For the MES study, the test groups 
contained 10 animals, 8 animals, and 7 animals for the vehicle, sodium valproate, and CI-2 and 
CI-6 treatments, respectively. 
 
In all cases, experiments were conducted in a blind manner with respect to the experimenters. 
Data were evaluated in Excel using one-tailed, unpaired Student’s t test, assuming populations 
with unequal variance. 
 
 2.4.2 Results and discussion 
 2.4.2.1 Inhibition of T-type calcium channel and seizure  
All of the synthesized small molecules (CI-1 to CI-10) were tested for their T-type calcium 
current inhibition. Five of the compounds (CI-1, CI-2, CI-3, CI-6 and CI-7) were tested for 
their inhibition selectivity towards sodium and potassium currents. Two of them (compound CI-
2 and CI-6) were further tested towards their inhibition of seizure induced death in mice models. 
The bio-evaluation results were summarized in Table 2.2. Except compounds CI-5, CI-8 and CI-
9, all other designed molecules showed inhibition towards T-type calcium currents. 
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In the seizure inhibition study of mice models, fatality rate is calculated as the percentage of 
mice within each treatment group that dies within the 20 min observation period. Fatality rate 
was used to characterize a CI compound's ability to prevent death resulting from PTZ-induced 
seizures. Percentage of inhibition of seizure induced death was used to show the final results in 
Table 2.2 and it was calculated as 100%-fatality rate. 
 
Code 
name 
Chemical structure 
Inhibition 
T-Ca 
% 1 μM 
Na 
% 1 μM 
K 
% 1 μM 
Inhibition 
of seizure 
induced 
death (%) 
CI-1 
S
Cl
O
NN
N Cl
Cl
O
O  
9.8 
(1, 3.3 μM) 
0 
(1, 3.3 μM) 
-17.8 
(3.3 μM) 
0 
CI-2 
S
Cl
O
NN
N
H
O Cl
 
20.4 
82.2 
(3.3 μM) 
-15.6 
(3.3 μM) 
29.6 
CI-3 
S
Cl
O
NN
N
H
O
 
24.4 -71.8 -28.6 NT 
CI-4 
S
Cl
O
NN
N
H
O
N N
H
O
 
79.5 NT NT NT 
CI-5 O
NN
N
H
O Cl
 
5 NT NT NT 
CI-6 O
NN
N
H
O
S
Cl  
50 
IC
50
=0.93 μM 
16.5 ±8.9% 
(n=7) 
24.1 72.1 
CI-7 O
NN
N
 
64.6± 14.1% 
(n=2) 
25.7 ±6.3% 
(n=5) 
21.9 ± 8.6% 
(n=4) 
NT 
CI-8 
O
NN
N
H
O
N
 
inactive NT NT NT 
CI-9 
O
NN
N
H
O
N
CN
 
inactive NT NT NT 
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CI-10 
O
NN
N
H
OF
S
Cl
 
60.9 NT NT NT 
Table 2.2. in vitro and in vivo Bioactivities of synthesized 1,3,4-oxadiazole derivatives. ( NT: 
not test) 
 
Among the active T-type calcium channel inhibitors, two compounds (CI-6 and CI-7) showed 
some extent selectivity in the inhibition of T-type calcium currents towards sodium and 
potassium currents. As summarized in Table 2.3, both CI-6 and CI-7 showed good inhibition (> 
50%) in T-type Ca
2+
 currents and lower inhibition (~20 %) of voltage-gated Na
+
 or K
+
 currents  
 
Code name Chemical structure 
Inhibition 
T-Ca 
% 1 μM 
Na 
% 1 μM 
K 
% 1 μM 
CI-6 O
NN
N
H
O
S
Cl  
50 
IC
50
=0.93 μM 
16.5 ±8.9 (n=7) 24.1 
CI-7 O
NN
N
 
64.6± 14.1% 
(n=2) 
25.7 ±6.3% (n=5) 21.9 ± 8.6% (n=4) 
Table 2.3. Compounds CI-6 and CI-7 showed selective T-type calcium channel inhibition. 
 
Studies on seizure induced death in mice models were performed on CI-2 and CI-6 and the 
results were summarized in Table 2.4. CI-2 had low inhibition (20% inhibition) towards T-type 
calcium channel and suppressed 29.6% seizure induced death. CI-6 was a better T-type calcium 
channel inhibitor (50% inhibition) and led to a prominent enhancement (from 29.6% to 72.1%) 
in the inhibition of seizure induced death. Results of seizure model studies indicated that 
inhibition of T-type calcium channels would lead to inhibition of seizure. Thus, T-type calcium 
channels could be a potential biological target for the treatment of epilepsy.  
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Code name Chemical structure 
Inhibition 
T-Ca 
% 1 μM 
Na 
% 1 μM 
K 
% 1 μM 
Inhibition of 
seizure 
induced 
death(%) 
CI-2 O
NN
N
H
O
S
Cl  
20.4 
82.2 
( 3.3 μm) 
-15.6 
( 3.3 μm) 
29.6 
CI-6 
S
Cl
O
NN
N
H
O Cl
 
50 
IC
50
=0.93 μM 
16.5 ±8.9 
(n=7) 
24.1 72.1 
Table 2.4. Inhibition results of seizure induced death in mice models for compounds CI-2 
and CI-6  
 
 2.4.2.2 Structure-activity relationship towards inhibition of T-type calcium channel 
As summarized in Table 2.5, the oxadiazole pharmacophore does not tolerate aliphatic rings in 
part B (compounds CI-5, CI-8 and CI-9), aromaticity (compounds CI-6 and CI-10) or rigidity 
(compound CI-7) is needed. Enhancement of T-type calcium channel inhibition can be achieved 
through further structural modification of in part A (compound CI-6 versus CI-10). 
 
NN
OR1 NH
Part A
Part B
O
R2
 
Code 
name 
Chemical Structral 
Inhibition 
T-Ca 
% 1 μM 
Code 
name 
Chemical Structral 
Inhibition 
T-Ca 
% 1 μM 
CI-5 O
NN
N
H
O Cl
 
5 CI-8 
O
NN
N
H
O
N
 
inactive 
CI-6 O
NN
N
H
O
S
Cl
 
50 CI-9 
O
NN
N
H
O
N
CN
 
inactive 
44 
CI-7 O
NN
N
 
64.6 CI-10 O
NN
N
H
OF
S
Cl
 
60.9 
Table 2.5. Structure-activity relationship (SAR) summary towards inhibition of T-type 
calcium channel. 
 
 2.4.2.3 Lead compound CI-6 versus reported T-type calcium channel inhibitor 
Z944 
Z944 (Figure 2.5) is a T-type calcium channel inhibitor reported by Zalicus Inc. in the year of 
2012
40
. It is a new drug discovered for the treatment of pain and now in initial phase two of 
clinical trial. Inhibitions of different channels (Ca
2+
, Na
+
, K
+
) by Z944 using patch clamp 
recordings were performed. The Z944 test results were compared with our lead compound CI-6 
as shown in Figure2.6. CI-6 had dose dependently effect on the inhibition of T-type Ca
2+
 
currents suggesting its specific inhibition (Figure 2.6.A). Unlike CI-6 that can selectively inhibit 
T-type Ca
2+
 over Na
+
 (Figure 2.6.B) and K
+
 currents (Figure 2.6.C), Z944 also blocked Na
+ 
currents in a dose dependently manner (Figure 2.6.D). 
FLIPR: fluoresent imaging plate reader
EP: electrophysiology
F
Cl
O
H
N
N
O
H
N
Z944, Zalicus
Cav3.2 IC50 = 0.05 μM (FLIPR)
O
NN
N
H
O
S
Cl
CI-6
T-type IC50 = 0.93 μM (EP)
 
Figure 2.5. Chemical structures of Z944 and compound CI-6. 
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Figure 2.6. CI-6 blocked the native T-type calcium currents recorded on DRG neurons in 
dose dependently manner (A). CI-6 slightly inhibited sodium (B) and potassium (C) 
mediated currents recorded on DRG. The effect was not dose dependently, suggesting the 
unspecific inhibition. (D) Z944 blocked the voltage dependent sodium currents. Each point 
represents the averaged data of 3-7 cells. (This figure was reprinted from Poster #152.08/M33, 
which was presented by Simon Xie, et al. at Neuroscience 2015 Annual Meeting in Chicago.
41
) 
 
 2.4.2.4 Concerns 
The bio-evaluations performed so far were just focused on the evaluation of efficacy. With an 
understanding of structure-activity relationship (SAR), more derivatives could be designed and 
synthesized in order to find more potent inhibitors in the future. However, attentions should not 
only be addressed on the improvement of potency. More explorations for their pharmacokinetics 
properties needed to be done in order to find lead compounds with good drug-like properties. 
One major drawback of the current designed 1,3,4-oxadiazole derivatives is poor solubility. 
Future structural optimization should pay more attention to the increase of solubility. 
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 2.5 Conclusion 
A series of 1,3,4-oxadiazole derivatives was designed and synthesized as T-type calcium channel 
blockers. The designed small molecules were screened for their ability and selectivity towards 
inhibition of T-type calcium channels. Two hit compounds (CI-6 and CI-7) were found to 
possess good inhibition on T-type Ca
2+
 currents and lower inhibition on voltage-gated Na
+
 or K
+
 
currents. Structure-activity relationship (SAR) was discussed based on the results of T-type 
calcium currents inhibition. Either aromaticity or rigidity is efficacy-necessary in the 
construction of part B. Studies on seizure models in mice showed that inhibition of T-type 
calcium channel could lead to inhibition of seizure induced death. Among various 1,3,4-
oxadiazole derivatives, compound CI-6 was found to be the lead compound. CI-6 was a good T-
type calcium channel inhibitor (IC50 = 0.93 μM), which could suppress 72% seizure induced 
death in mice models. Further structural optimization of CI-6 could be conducted in the future to 
discover more potent inhibitors with better drug-like properties. 
 
 2.6 Synthetic experimental procedures 
 2.6.1 General 
Chemicals were purchased from Fisher Scientific, VWR international LLC and Chem-Impex 
International, Inc.. NMR spectra were taken from a 400 MHz Spectrometer (Varian Inc.) in 
chloroform-D unless otherwise informed. Mass spectra were obtained from an API 2000-triple 
quadrupole ESI-MS/MS mass spectrometer (Applied Biosystems).  
 
 2.6.2 Representative synthesis 
 2.6.2.1 N-(Carbamothioylamino)-5-chlorothiophene-2-carboxamide (Compound 2-2) 
H2N
H
N
N
H
S
O
S
Cl
2-2  
To a solution of 1 g (6.1 mmol, 1 equiv.) of 5-chlorothiophene-2-carboxylic acid (commercially 
available from Chem-Impex International, Inc.) in 13 mL of distilled ethyl acetate at 0
o
C, 940 
47 
mg (7.4 mmol, 1.2 equiv.) of oxalyl chloride was added followed by the addition of 2 drops of 
distilled N,N-dimethyl formamide (DMF). The resulting reaction solution was kept stirring under 
argon at 0
o
C for 2 h and concentrated to dryness to yield 5-chlorothiophene-2-carbonyl chloride. 
The crude acyl chloride was directly used in the next step without further purification, assuming 
the yield of 5-chlorothiophene-2-carbonyl chloride was 100%. 
 
A suspension of 1.22 g (13 mmol, 2.2 equiv.) of thiosemicarbazide (compound 2-1, 
commercially available from Chem-Impex International, Inc.) in 10 mL of distilled THF was 
cooled to 0
0
C under argon. To it, a solution of 1.105g (6.1mmol, 1 equiv.) of 5-chlorothiophene-
2-carbonyl chloride in 10 mL of distilled THF was added slowly under argon at 0
0
C. Allowed 
the resulting reaction mixture to slowly warm to room temperature and kept it stirring overnight. 
To the reaction mixture, 100 mL of distilled water was added. The precipitated white solid crude 
product was collected by filtration, washed with distilled water, and dried under vacuum to yield 
870 mg (60% yield) of compound 2-2 as a white solid. 
1
H NMR (DMSO-d6) δ ppm 7.22 (d, 
J=4.30 Hz, 1 H) 7.61 - 7.76 (m, 2 H) 7.92 (br. s., 1 H) 9.37 (br. s., 1 H) 10.50 (s, 1 H).  MS 
(positive mode), m/z calcd for C6H6ClN3OS2Na (M+Na)
+
 258.0, found 258.3. 
 2.6.2.2 1-Benzoyl-3-thiosemicarbazide (Compound 2-3) 
H2N
S
H
N
N
H
O
2-3  
A suspension of 4 g (43.8mmol, 2.2 equiv.) of thiosemicarbazide (compound 2-1, commercially 
available from Chem-Impex International, Inc.) in 100 mL of distilled THF was cooled to 0
0
C 
under argon. To it, a solution of 2.8 g (19.91mmol, 1equiv.) of benzoyl chloride (commercially 
available from Fisher Scientific) in 20 mL of distilled THF was added slowly under argon at 0
0
C. 
Allowed the resulting reaction mixture to slowly warm to room temperature and kept it stirring 
under argon overnight. Reaction solution was concentrated to get rid of most THF. To the 
reaction residue, 100 mL of distilled water and 10 mL of saturated NaHCO3 solution were added. 
The precipitated white solid crude product was collected by filtration, washed with hexane and 
dried under vacuum to yield 3.8 g (100% yield) of compound 2-3 as a white solid. 
1
H NMR 
(DMSO-d6) δ ppm 1.91 (m, J=7.00 Hz, 1 H) 7.47 (t, J=7.13 Hz, 2 H) 7.51 - 7.59 (m, 1 H) 7.62 
48 
(br. s., 1 H) 7.79 - 7.93 (m, 3 H) 9.36 (br. s., 1 H).  MS (positive mode), m/z calcd for 
C8H9N3OSNa (M+Na)
+
 218.05, found 218.1. 
 2.6.2.3 5-(5-Chlorothiophen-2-yl)-1,3,4-oxadiazol-2-amine (Compound 2-4) 
SCl
O
NN
NH2
2-4  
A solution of 612 mg (3.69 mmol, 0.3 equiv.) of KI in 7 mL of distilled water was cooled to 0
0
C. 
To it, 2.9 g of compound 2-2 (12.3 mmol, 1 equiv.) was added followed by 20 mL of distilled 
water and 4.6 mL of 4N NaOH aqueous solution (18.45mmol, 1.5 equiv.). To the resulting 
solution, 3.87 g of 1,3-dibromo-5,5- dimethylhydantoin (13.53 mmol, 1.1 equiv, commercially 
available from Chem-Impex International, Inc.) was added. The resulting mixture was kept 
stirring under argon at room temperature for 7 h. To the reaction mixture, 3.6 mL of saturated 
NaHSO3 aqueous solution was added. Aqueous layer was extracted four times with ethyl acetate 
(150 mL each time). Combined organic layers were washed with brine, dried over Na2SO4, 
filtered, and concentrated. Crude product was crystallized from ethyl acetated (80 mL) to yield 
1.2 g (49% yield) of compound 2-4 as yellow crystals. 
1
H NMR (DMSO-d6) δ ppm 7.24 (d, 
J=4.30 Hz, 1 H) 7.33 - 7.38 (m, 3 H). 
13
C NMR (DMSO-d6) δ ppm 163.5, 152.6, 130.7, 128.2, 
126.9, 124.6.  MS (positive mode), m/z calcd for C6H5ClN3OS (M+H)
+
 202.0, found 202.0. 
 2.6.2.4 5-Phenyl-1,3,4-oxadiazol-2-amine (Compound 2-5) 
O
NN
NH2
 2-5  
Procedure was similar to the synthesis of compound 2-4 (see section 2.6.2.3). Started from 3.8 g 
(19.48 mmol, 1equiv.) of compound 2-3, 1.3 g (41% yield) of compound 2-5 was obtained as 
yellow crystals after crystallization. 
1
H NMR (DMSO-d6) δ ppm 7.28 (br. s., 2 H) 7.40 - 7.62 (m, 
3 H) 7.68 - 7.94 (m, 2 H).  MS (positive mode), m/z calcd for C8H8N3O (M+H)
+
 162.06, found 
162.3. 
 2.6.2.5 5,6-Dichloro-2-(5-(5-chlorothiophen-2-yl)-1,3,4-oxadiazol-2-yl)isoindoline-1,3-
dione (Compound CI-1) 
49 
S
Cl
O
NN
N Cl
Cl
O
O
CI-1  
To a solution of 94 mg (0.35 mmol, 1 equiv.) of 4,5-dichlorophthalic acid in 4 mL of distilled 
dichloromethane at 0
o
C, 107 mg (0.84 mmol, 2.4 equiv.) of oxalyl chloride (commercially 
available from Fisher Scientific) was added dropwise followed by adding 1 drop of distilled 
DMF. The resulting reaction solution was kept refluxing under argon for 3.5 h and concentrated 
to dryness to give 95 mg (100% yield) of 4,5-dichlorobenzene-1,2-dioyl dichloride as a white 
solid. The formed 4,5-dichlorobenzene-1,2-dioyl dichloride was directly used for next step 
without purification 
 
To a suspension of 70 mg (0.35 mmol, 1 equiv.) of compound 2-4 in 3 mL of distilled 
dichloromethane, was added 82 mg (1.04 mmol, 3 equiv.) of anhydrous pyridine and allowed the 
resulting mixture to cool to 0
o
C under argon. To it, a solution of 95 mg (0.35 mmol, 1 equiv.) 
4,5-dichlorobenzene-1,2-dioyl dichloride in 0.5 mL of distilled dichloromethane was added 
dropwise at 0
o
C and kept stirring under argon at room temperature for 5 h. The resulting reaction 
solution was partitioned between 200 mL of dichloromethane and 30 mL of 10% aqueous 
NaHCO3 solution. Organic layer was isolated and washed with brine, dried over Na2SO4, 
filtered, concentrated and column chromatographed on silica gel using a gradient mixture of 
hexane and ethyl acetate as eluent to give 30 mg (22% yield) of compound CI-1 as a beige solid. 
1
H NMR (DMSO-d6) δ ppm 7.40 (d, J=4.00 Hz, 1 H) 7.75 (d, J=4.00 Hz, 1 H) 8.40 - 8.48 (m, 2 
H). 
13
C NMR (DMSO-d6) δ ppm 161.7, 159.3, 151.2, 138.7, 134.4, 131.1, 131.0, 129.0, 126.5, 
122.1.  MS (positive mode), m/z calcd for C14H4Cl3N3O3SNa (M+Na)
+
 421.9, found 422.0. 
 2.6.2.6 3-(3-Chlorophenyl)-N-(5-(5-chlorothiophen-2-yl)-1,3,4-oxadiazol-2-
yl)propanamide (Compound CI-2) 
S
Cl
O
NN
N
H
O Cl
CI-2  
50 
To a solution of 46 mg (0.25 mmol, 1 equiv.) of 3-(3-Chlorophenyl)propionic acid 
(commercially available from Chem-Impex International, Inc.) in 3 mL of distilled ethyl acetate 
at 0
o
C, 38 mg (0.30 mmol, 1.2 equiv.) of oxalyl chloride was added followed by adding 1 drop of 
distilled DMF. The resulting reaction solution was kept stirring under argon at 0
o
C for 2 h and 
concentrated to dryness to produce 3-(3-chlorophenyl)propanoyl chloride as a white solid. The 
crude acyl chloride was directly used for next step without further purification, assuming the 
yield of 3-(3-chlorophenyl)propanoyl chloride was 100%. 
 
To a suspension of 50 mg (0.25 mmol, 1 equiv.) of compound 2-4 in 3 mL of distilled 
dichloromethane under argon, was added 30 mg (0.38 mmol, 1.5 equiv.) of anhydrous pyridine. 
To the resulting reaction mixture, a solution of 50 mg (0.25 mmol, 1 equiv.) of 3-(3-
chlorophenyl)propanoyl chloride in 0.3 mL of distilled dichloromethane was added and kept 
stirring at room temperature under argon for 5 h. The resulting reaction solution was partitioned 
between 300 mL of ethyl acetate and 40 mL of 10% aqueous NaHCO3 solution. Organic layer 
was isolated and washed with brine, dried over Na2SO4, filtered, concentrated and column 
chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate as eluent to 
produce 59 mg (64% yield) of compound CI-2 as a white solid. 
1
H NMR (DMSO-d6) δ ppm 2.78 
(t, J = 7.42 Hz, 2 H) 2.91 (t, J = 7.42 Hz, 2 H) 7.16 - 7.41 (m, 5 H) 7.55 (d, J = 3.91 Hz, 1 H). 
13
C 
NMR (DMSO-d6) δ ppm 169.8, 156.9, 155.6, 143.3, 132.9, 132.6, 130.2, 129.1, 128.6, 128.2, 
127.1, 126.1, 123.3, 36.8, 29.5.  MS (positive mode), m/z calcd for C15H11Cl2N3O2SNa (M+Na)
+
 
390.0, found 389.9. 
 2.6.2.7 N-(5-(5-Chlorothiophen-2-yl)-1,3,4-oxadiazol-2-yl)benzamide (Compound CI-
3) 
SCl
O
NN
N
H
O
CI-3  
To a solution of 70 mg of compound 2-4 (0.347 mmol, 1eq) in 3mL of distilled dichloromethane 
under argon, 40 μL of anhydrous pyridine (0.347 mmol, 1eq) was added. Allowed the resulting 
reaction mixture to cool to 0
0
C. To it, 73 mg of distilled benzoyl chloride (0.520 mmol, 1.5 eq) 
was slowly added under argon at 0
0
C. Allowed it to slowly warm to room temperature and kept 
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stirring for 4 h at room temperature. Reaction solution was diluted with 200 mL of 
dichloromehane. Organic layer was isolated and washed with saturated NaHCO3 aqueous 
solution, brine, dried over Na2SO4, filtered, and concentrated. Crude product was crystallized 
from ethanol to produce 5 mg (6% yield) of compound CI-3. 
1
H NMR (DMSO-d6) δ ppm 7.27 - 
7.39 (m, 1 H) 7.47 - 7.59 (m, 2 H) 7.59 - 7.73 (m, 3 H) 7.98 - 8.10 (m, 2 H).  MS (positive 
mode), m/z calcd for C13H8CN3O2SNa (M+Na)
+
 328.0, found 328.0. 
 2.6.2.8 2-(4-Cyanopiperidin-1-yl)-N-phenylacetamide (Compound 2-6-3) 
N
CN
O
H
N
2-6-3  
To a mixture of 3 g (17.7 mmol) of 2-chloro-N-phenylacetamide (compound 2-6-2) and 4.88 g 
(35.3 mmol) of anhydrous K2CO3 in 25 mL of distilled acetonitrile was added 1.95 g (17.7 
mmol) of 4-cyanopiperidne (compound 2-6-1). The resulting reaction mixture was refluxed 
under argon for 8 h. Organic layer was isolated by filtration, concentrated, and column 
chromatographed on silica gel using a gradient mixture of dichloromethane and methanol as 
eluent to give 4.28 g (99% yield) of compound 2-6-3 as a while solid. 
1
H NMR δ ppm 1.81 - 
2.23 (m, 4 H) 2.35 - 2.93 (m, 4 H) 3.10 (s, 2 H) 7.09 (dd, J = 7.80 Hz, 1 H) 7.31 (dd, J = 7.80 Hz, 
2 H) 7.48 - 7.63 (m, 2 H). 
13
C NMR δ ppm 167.9, 137.5, 129.1 (2C), 124.4, 121.3, 119.6 (2C), 
62.3 (2C), 51.9, 29.0 (2C), 25.6.  MS (positive mode), m/z calcd for C14H18N3O (M+H)
+
 244.0, 
found 244.5. 
 2.6.2.9 1-((Phenylcarbamoyl)methyl)-N-(5-(5-chlorothiophen-2-yl)-1,3,4-oxadiazol-2-
yl)piperidine-4-carboxamide (Compound CI-4) 
S
Cl
O
NN
N
H
O
N N
H
O
CI-4  
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To a solution of 138 mg (0.57 mmol, 1 equiv.) of compound 2-6-3 in 5 mL of methanol, 2 mL of 
3N NaOH aqueous solution was added and kept refluxing overnight. Concentrated reaction 
solution to get rid of most methanol. Resulting residue was neutralized with 2 N HCl aqueous 
solution and lyophilized to dryness under vacuum to yield compound 2-6 together with NaCl as 
white solids mixture. The crude mixture was directly used for next step without further 
purification, assuming the yield of carboxylic acid 2-6 was 100%. 
 
A mixture of 150 mg (0.57 mmol, 1 eaquiv.) of compound 2-6, 114 mg (0.57 mmol, 1 equiv.) of 
compound 2-4, 328 mg (1.71 mmol, 3 equiv.) of EDC and 209 mg (1.71 mmol, 3 equiv.) of 
DMAP in 2 mL of distilled DMF and 2mL of distilled dichloromethane was kept stirring at 50
o
C 
overnight under argon. The resulting reaction mixture was diluted with 40 mL of distilled water 
and adjusted to pH = 3 using 2N HCl aqueous solution. The resulting aqueous layer was 
extracted with dichloromethane twice. Combined organic layers were washed with brine, dried 
over Na2SO4, filtered, concentrated and column chromatographed on silica gel using a gradient 
mixture of dichloromethane and methanol as eluent to give 28 mg (11% yield) of compound CI-
4 as a beige solid. 
1
H-NMR: (400 MHz, DMSO-d6) δ ppm1.67-1.90 (m, 4H), 2.2 (t, J=11.13 Hz, 
2H), 2.87-2.97 (m, 3H), 3.13 (br. s., 2 H), 7.05 (dd, J=7.20 Hz, 1H), 7.26-7.36 (m, 3H), 7.57 (d, 
J=3.91 Hz, 1H), 7.64 (d, J=8.20 Hz, 2H), 9.69 (br.s., 1H, NH), 11.82 (br.s., 1H, NH).  MS 
(positive mode), m/z calcd for C20H21ClN5O3S (M+H)
+
 446.1, found 446.3. 
 2.6.2.10 5-Chloro-N-(5-phenyl-1,3,4-oxadiazol-2-yl)thiophene-2-carboxamide 
(Compound CI-6) 
O
NN
N
H
O
S
Cl
CI-6  
The synthesis of 5-chlorothiophene-2-carbonyl chloride was discussed before (see section 
2.6.2.1). 
 
To a solution of 300 mg (1.86 mmol, 1 equiv.) of compound 2-5 in 10 mL of distilled 
dichloromethane, 220 mg (2.79 mmol, 1.5 equiv.) of anhydrous pyridine was added and allowed 
it to cool to 0
o
C. To it, a solution of 337 mg (1.86 mmol, 1equiv.) of 5-chlorothiophene-2-
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carbonyl chloride in 5 mL of distilled dichloromethane was added dropwise. The resulting 
reaction mixture was kept stirring under argon at room temperature for 3.5 h. Resulting reaction 
solution was diluted with 40 mL of 10% NaHCO3 aqueous solution and extracted with 
dichloromethane three times. Combined organic layers were washed with brine, dried over 
Na2SO4, filtered, concentrated and column chromatographed on silica gel using a gradient 
mixture of hexane and ethyl acetate as eluent to give 300 mg (53% yield) of compound CI-6 as a 
white solid. 
1H NMR δ ppm 7.06 (d, J=4.30 Hz, 1 H) 7.49 - 7.67 (m, 3 H) 7.98 (d, J=7.42 Hz, 2 
H) 8.12 (d, J=4.30 Hz, 1 H) 8.22 (br. s., 1 H). 
13
C NMR δ ppm 158.2, 154.3, 151.3, 142.1, 137.3 
133.3, 129.9, 129.4, 127.2, 127.1, 122.4.  MS (positive mode), m/z calcd for C13H8ClN3O2SNa 
(M+Na)
+
 328.0, found 327.8. 
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Chapter 3 - Synthesis and bioevaluation of tricyclic pyrone 
derivatives for the treatment of Alzheimer’s disease (AD)  
 3.1 Background and significance 
 3.1.1 Alzheimer’s disease (AD)  
Alzheimer's disease(AD) is defined as “a progressive, degenerative disorder that attacks the 
brain's nerve cells, or neurons, resulting in loss of memory, thinking and language skills, and 
behavioral changes”1 and it is now the sixth leading cause of death in the United States.2 Current 
drugs can only alleviate symptoms but not prevent progression of the disease, until now AD is 
still not curable.
3,4
 Nowadays there are only five FDA approved drugs in the market for the 
treatment of Alzheimer’s Disease as shown in Table 3.1.2 Discovery of new anti-AD drugs and 
exploration on the mechanism of disease development are needed.  
Drug Name Chemical Structure 
Brand 
Name 
Approved 
for 
FDA 
approved 
Action 
Mechanism
5
 
Donepezil O
O
O
N
 
Aricept All stages 1996 
reversible acetyl 
cholinesterase 
inhibitor 
Galantamine 
O
O
H
N
HO  
Razadyne 
Mild to 
moderate 
2001 
cholinesterase 
inhibitor 
Memantine 
NH2
 
Namenda 
Moderate to 
severe 
2003 
NMDA receptor 
antagonist 
Rivastigmine 
ON
O
N
H
 
Exelon All stages 2000 
cholinesterase 
inhibitor 
Donepezil and 
memantine 
see above Namzaric 
Moderate to 
severe 
2014  
Table 3.1. FDA approved drugs for the treatment of Alzheimer’s disease. (The table was 
adapted from alz.org website
2
) 
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 3.1.2 Previous studies on tricyclic pyrone compounds as anti-Alzheimer’s disease 
drugs 
Although the cause of AD is still not clear. It is widely accepted that aggregates of amyloid-β 
(Aβ) peptides play an important role in the development of AD through initiating a cascade of 
molecular changes.
6
 The Aβ peptides aggregate to form oligomers, which are toxic to neurons 
and precipitate to form fibrils which are found in AD brains and finally lead to neuronal cell 
death
7
. Attentions have been drawn to develop molecules which can prevent, or reduce the 
aggregation of Aβ peptides for the treatment of AD. Previous studies conducted by the Hua 
group
7-14
 have discovered a new class of tricyclic pyrone compounds, which have good oral 
bioavailability and low toxicity, can reduce Aβ aggregation in the brain. The tricyclic pyrone 
scaffold was derived from natural product (+)-pyripyropene A (Figure 3.1), a well-known 
cholesterol acyltransferase (ACAT) inhibitor
15
. ACAT is a cholesterol-regulating enzyme, which 
was found to be related with increasing Aβ levels in the brain and its inhibition has been reported 
as a potential anti-AD therapeutic strategy.
16
 Exploration on more neuronal protective tricylic 
pyrone compounds are still needed for the treatment and mechanism study of AD. 
O
OO N
HO
OAc
H
H
AcO
AcO
(+)-pyripyropene A  
Figure 3.1. Chemical structure of (+)-pyripyropene A. 
 
 3.2 Research objectives 
Research objective 1: Synthesis of neuronal protective tricyclic pyrone molecules for the study 
of amelioration of Alzheimer’s disease.  
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Research objective 2: Study of pharmacokinetics properties of discovered active tricyclic 
pyrone derivatives.  
 
 3.3 Syntheses of tricyclic pyrone compounds 
CP2 (code name; chemical structure see Figure 3.2) was a reported lead anti-Alzheimer’s 
compound from Hua group and has been studied extensively for its bio-activities and 
mechanisms of action.
7,9-11,14
 In order to discover competitive lead compounds, a series of 
tricyclic pyrone compounds as shown in Figure 3.2 was screened for their neuronal protective 
properties. I was involved in the syntheses of compounds TP70, TP82 and CP2. Dr. Laxman 
Pokhrel in Hua group has previously synthesized a small library of tricyclic pyrone compounds 
including TP70 and TP82 as shown in Figure 3.2.
11
 However, since large amounts of TP70 and 
CP2 were needed for pharmacokinetics study, I therefore synthesized these two compounds in 
large quantities and high purities. 
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O
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O
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Figure 3.2. Chemical structures of tricyclic pyrone compounds.
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 3.3.1 Synthetic routes 
Syntheses of compounds TP70, TP82 and CP2 were followed by reported procedures (Laxman 
Pokhrel et al
11
. 2012; Duy H. Hua et al
8
. 2003). All synthesized molecules were characterized by 
1
H NMR and MS, the spectra are identical to those reported. Construction of the basic tricyclic 
pyrone skeleton was shown in Scheme 3.1. L-proline acted as a catalyst to activate aldehyde 
group in (S)-(-)-perillaldehyde (compound 3-2) by forming iminium intermediate, which 
subsequently condensed and cyclized with 6-methyl-4-hydroxy-2-pyrone (compound 3-1) to 
give tricyclic pyrone intermediate 3-3. Possible explanation of the stereoselectivity in the 
synthesis of compound 3-3 was shown in Scheme 3.2. Bulky isopropenyl group blocks down 
face in the proposed intermediate 3-3-7, so the electron lone pair in carbonyl oxygen prefers to 
attack from the up face leading to the stereoselectivity. 
OO
OH
3-1
CHO
3-2
+
L-proline 
EtOAc
reflux, 2d
O
O
O
H
H
3-3
yield : 68%
 
Scheme 3.1. Synthesis of isopropenyl-substituted tricyclic pyrone intermediate (compound 
3-3). 
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Scheme 3.2. Possible explanation of the stereoselectivity in the synthesis of compound 3-3. 
 
Syntheses of compounds TP70 and TP82 were shown in Scheme 3.3. The tricyclic pyrone 
alkene 3-3 went through hydroboration with borane followed by amination with hydroxylamine-
o-sulfonic acid to give amine 3-4, which underwent reductive amination reactions with different 
aromatic aldehydes (3-5 or 3-6) and sodium cyanoborohydride in ethanol to yield TP70 and 
TP82, respectively. 
a) BH3
. THF, rt, overnight
b) S
OO
OHO
NH2
reflux, overnight
O
O
O
H
H
NH2
3-4
yield: 40%
O
O
O
H
H
3-3
+
OH
n
O
H
n=0:  3-5
n=1:  3-6
a) EtOH, rt, overnight
b) NaBH3CN/ H
+
O
O
O
H
H
H
N
n=0:  TP70     yield: 51%
n=1:  TP82     yield: 61%
OHn
 
Scheme 3.3. Syntheses of compounds TP70 and TP82. 
 
Synthesis of CP2 was shown in Scheme 3.4. The tricyclic pyrone alkene 3-3 underwent 
hydroboration–oxidation reaction to produce alcohol 3-7, which was first converted into the 
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mesylate by the treatment with methanesulfonyl chloride and then displacement with adenine in 
N,N-dimethylacetatmide (DMA) under reflux reaction conditions to give compound CP2. 
 
a) BH3
. THF, rt, overnight
b) 30% H2O2, 0.3% NaOH
O
O
O
H
H
OH
3-7
yield: 77%
O
O
O
H
H
3-3
Et3N, CH2Cl2
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4 hr
S
O
O
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O
O
O
H
H
O
3-8
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S
OO
O
O
O
H
H
N
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yield: 13.5%
N
N
N
NH2
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N,N-dimethyl 
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reflux, overnight
 
Scheme 3.4. Synthesis of compound CP2. 
 
 3.3.2 Purification of CP2 
In order to achieve high purity, CP2 was column chromatographed on silica gel twice followed 
by crystallization and recrystallization. The purity of CP2 was determined by HPLC conducted 
by Dr. Gaochao Huang in Dr. Ping Li’s laboratory at the Department of Chemistry, Kansas State 
University. According to HPLC analysis, the purity of synthesized CP2 is as high as 97.25%. 
 
 3.3.2.1 Column chromatography 
 First time column chromatography 
 Silica gel was mixed with solvents containing ethyl acetate: dichloromethane: 
methanol = 4:6:1 + 0.5% NH3·H2O (volume ratio) before packing column. 
 Packed a short and fat column. 
 A gradient mixture of ethyl acetate, dichloromethane and methanol was used as 
eluent: 
1) 100% ethyl acetate 
2) ethyl acetate: dichloromethane: methanol = 4:6:1 (volume ratio) 
3) ethyl acetate: dichloromethane: methanol = 2:3:1 (volume ratio, CP2 eluted out) 
4) dichloromethane: methanol = 5:1 (volume ratio) 
 High air pressure was applied when running the column and first column was 
supposed to be run in a fast way with the purpose to get rid of the most nonpolar and 
most polar impurities. For example, started from 11 g crude product, 3.6 g product 
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CP2 together with impurities having similar polarities were obtained after first time 
column chromatography. 
 Second time column chromatography 
 Silica gel was mixed with solvents containing ethyl acetate: dichloromethane: 
methanol = 4:6:1 + 0.5% NH3·H2O (volume ratio) before packing column. 
 Packed a long column. 
 A gradient mixture of ethyl acetate, dichloromethane and methanol was used as 
eluent: 
1) 100% ethyl acetate 
2) ethyl acetate: dichloromethane: methanol = 4:6:1 (volume ratio) 
3) ethyl acetate: dichloromethane: methanol = 2:3:1 (volume ratio, CP2 eluted out) 
 Moderate air pressure was applied when running this column and the 2nd column was 
supposed to be run in a slower way with the purpose to get rid of most impurities 
having similar polarities to CP2. For example, started from 2.2 g impure CP2 
collected from first time column chromatography, 1.6 g CP2 together with small 
amount of less polar impurities were obtained after second time column 
chromatography. 
 
 3.3.2.2 Crystallization and recrystallization 
 Crystallization 
 In a beaker, 1.6 g CP2 obtained after second time column chromatography was 
dissolved in 40 mL dichloromethane after gentle heat.  
 To it, 20 mL diethyl ether was added and yellow solid was crystallized out. The 
resulting mixture was heated at 35
o
C for a while followed by sonication. Still 
small amount of yellow solid was not completely dissolved. 
 Allowed the resulting mixture to cool to room temperature, kept in an ice bath and 
kept in fridge (4
o
C) overnight. 1.1 g CP2 was obtained as yellow crystals by 
filtration and dried under vacuum. 
 Recrystallization 
 In a beaker, 320 mg CP2 crystals obtained from first crystallization was dissolved 
in 10 mL dichloromethane after gentle heat.  
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 To it, 30 mL diethyl ether was added and yellow solid was crystallized out. The 
resulting mixture was heated at 35
o
C for a while followed by sonication. Still 
small amount of yellow solid was not completely dissolved. 
 Allowed the resulting mixture to cool to room temperature, kept in an ice bath and 
kept in fridge (4
o
C) overnight. 240 mg pure CP2 was obtained as yellow crystals 
by filtration and dried under vacuum. 
 NOTE: Mother liquids from crystallization and recrystallization should be collected and 
saved for future purification. Do not discard the mother liquid. 
 
 3.3.2.3 Purity determination by HPLC analysis 
HPLC analysis was conducted by Dr. Gaochao Huang in Dr. Ping Li’s laboratory at the 
Department of Chemistry, Kansas State University. 
 HPLC sample preparation: 
 CP2 sample: 1 mg pure CP2 (obtained from recrystallization) was dissolved in 1 
mL methanol.  
 Blank sample: 100% methanol 
 HPLC instrument information: 
 Waters 2998 Photodiode Array Detector and Waters 1525 Binary HPLC Pump. 
 HPLC Column information: 
 Part Number: 00G-4252-E0 
 Description: Luna® 5 µm C18(2) 100 Å, LC  
 Column 250 x 4.6 mm, Ea 
 S/No. 676866-5 
 B/No. 529-112 
 Stationary Phase:C18 with TMS endcapping 
 Solid Support: Fully Porous Silica 
 Format: Column 
 Separation Mode: Reversed Phase 
 HPLC methods: 
 Eluents: A= water, B= methanol. A gradient mixture of water (solvent A) and 
methanol (solvent B) was used as eluent as shown in Table 3.2. 
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 Both the blank (100% methanol) and CP2 samples (concentration: 1mg CP2 in 1 
mL methanol) were analyzed using the same method (Table 3.2). 
 CP2 has the maximum UV absorption at wavelength 269.1 nm as shown in 
Figure 3.3. 
 Time Flow %A %B %C Curve 
1 0.01 1.00 70.0 30.0 0.0 6 
2 30.00 1.00 10.0 90.0 0.0 6 
3 33.00 1.00 10.0 90.0 0.0 6 
4 39.00 1.00 70.0 30.0 0.0 6 
5 42.00 1.00 70.0 30.0 0.0 6 
Table 3.2. A gradient mixture of water (solvent A) and methanol (solvent B) was used as 
HPLC eluent (conducted by Dr. Gaochao Huang in Dr. Li’s laboratory).  
 
 
Figure 3.3. UV absorption spectrum of CP2 (conducted by Dr. Gaochao Huang in Dr. Li’s 
laboratory). 
 
 HPLC analysis results: 
 Purity of synthesized CP2 after recrystallization is 97.25% as shown in Table 3.3. 
 HPLC graph (Figure 3.4) for CP2 was drawn according to the data at wavelength 
269.1nm, where CP2 has the maximum UV absorption (see Figure 3.3). 
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Figure 3.4. Purity of obtained CP2 after recrystallization was determined by HPLC 
(conducted by Dr. Gaochao Huang in Dr. Li’s laboratory). 
 
 Retention Time Area % Area Height Peak Codes 
1 10.418 121947 0.39 5853 I08 
2 13.720 75188 0.24 3965  
3 14.395 117769 0.38 3931  
4 15.316 20382 0.07 1449 I08 
5 15.950 81129 0.26 3398  
6 17.051 84195 0.27 2344  
7 20.236 30425249 97.25 931718  
8 21.824 204762 0.65 9349 I08 
9 22.653 118849 0.38 2738  
10 27.093 35244 0.11 1394  
Table 3.3. Analysis for CP2 HPLC data (conducted by Dr. Gaochao Huang in Dr. Li’s 
laboratory). 
 
 3.4 Bioevaluation and discussion 
Bioevaluation was performed by Dr. Izumi Maezawa in Professor Lee-Way Jin’s laboratory at 
the Department of Pathology and Laboratory Medicine, University of California Davis Medical 
Center. Quantification of lead compound TP70 in plasma and various tissues using HPLC 
analysis was carried out by Dr. Sahani Weerasekara in Hua group. 
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Neuronal protective studies in cell-based assay were performed among nine tricyclic pyrone 
compounds (chemical structures, see Figure 3.2). Except compounds TP49 and TP67, all other 
compounds showed neuronal protective activities. TP70 was found to be another lead compound 
(with similar efficacy to the well-studied CP2) and its pharmacokinetics properties were further 
explored. 
  
 3.4.1 Methods  
 3.4.1.1 Studies on in vitro neuronal protective properties  
Following reported procedure
9,10,17
, nine tricyclic pyrone compounds (see Figure 3.2) were 
screened for their in vitro neural protectivities against cell death using MC65 cell line and the 
results were shown in Table 3.4 and Figure 3.6. According to previous studies done in the Jin 
group
9,10
, MC65 cell line was used in measuring the neuronal protective efficacy of the tricyclic 
pyrone derivatives and it is a line of human neuroblastoma that was engineered to conditionally 
expresses C99. C99 is a 99-residue fragment derived from amyloid processor protein (APP) and 
can be subsequently cleaved to produce Aβ peptides. The resulting MC65 cell toxicity was 
induced by oligomeric Aβ peptides, and was determined using a MTT assay.  
 
A general procedure for mesuring in vitro neuronal protective properties was summarized in 
Figure 3.5. 
 
Figure 3.5. General procedure for measuring in vitro neuronal protective properties 
(conducted in Dr. Jin group). 
71 
 
 3.4.1.2 Studies on pharmacokinetics properties 
Quantification of lead compound TP70 in plasma and various tissues using HPLC analysis was 
carried out by Dr. Sahani Weerasekara in Hua group following reported methods.
17
 
 
 3.4.2 Results and discussion 
 3.4.2.1 Studies on in vitro neuronal protective properties 
Entry Code Name ED50 (μM) TD50(μM) TI 
1 CP2 0.12 39 325 
2 TP4 0.26 77 296 
3 TP13 1.2 >25 >21 
4 TP36 0.175 51 291 
5 TP49 inactive (>5) N/A N/A 
6 TP67 inactive (>5) N/A N/A 
7 TP70 0.08 51 291 
8 TP82 0.09 77 855 
9 TP101 0.07 50 714 
Table 3.4. Results for in vitro neuronal protective efficacy of screened tricyclic pyrone 
compounds. ED50: effective dose for 50% cell survival. TD50: toxic effect for 50% cell death. 
TI: therapeutic ratio = TD50/ ED50  
 
According to Table 3.4, except compounds TP49 and TP67 (Entry 5 and 6) which are not active 
with high ED50 values (>5 μM), all other compounds are active with high TI (therapeutic ratio = 
TD50/ ED50) values, referring to low toxicities and high efficiencies. Except TP13 (ED50 = 1.2 
μM), six of the seven active compounds (CP2, TP4, TP13, TP36, TP70, TP82, and TP101) 
showed low nanomolar range ED50 values ranging from 0.07 to 0.26 μM.  
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Figure 3.6.A indicated that both compounds TP67 and TP70 showed dose-dependent response 
curves. Considering that TP67 was an inactive compound (with EC50 > 5 μM), it is TP70 that 
reduced the levels of intracellular C99 and oligomeric Aβ peptides (AβO), including low-n-
oligomers such as Aβ dimer and high-n-oligomers such as homo- or hetero-oligomeric 
complexes of Aβ (Aβ-OC) as shown in Figure 3.6.B.  
 
Previous researches done in the Jin group found that α-tocopherol, as an anti-oxidant, inhibited 
MC65 cells death
18
. CM-H2DCFDA was used to stain cellular reactive oxidative species (ROS) 
following reported procedure
7
. According to Figure 3.6.C, TP70 was found to have comparable 
anti-oxidant activity to α-tocopherol in reducing cell death by blocking ROS production of 
MC65 cells. No such anti-oxidant effects were found in compounds CP2 and TP67 as shown in 
Figure 3.6.C. 
 
 
Figure 3.6. The neuroprotective effects of TP70.  (A) MC65 cells were induced to express 
oligomeric Aβ peptides (AβO) by withdrawal of tetracycline (TC-) from the medium in the 
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presence of indicated concentrations of TP70 or TP67. Cultures in the presence of TC (TC+) as 
well as the drug were used as controls to determine the toxicity of the drug independent of Aβ. 
At 72 h, viability was assessed by MTT assay. Data are expressed as mean percentage viability 
(n=3) with parallel TC+ cultures without drug set at 100% viability. Error bars represent standard 
error. The ED50, TD50, and TI values of TP70 were calculated and listed in Table 3.4.  (B) MC65 
cultures at 24 h after TC withdrawal were homogenized and 5 μg cellular proteins were subjected 
to Tris/tricine SDS-PAGE and western blot analysis with antibody 6E10 for Aβ1-17. The band 
pattern was comparable to published data
10,19
; accordingly each band was identified. Both CP2 
and TP70, but not TP67, reduced the levels of Aβ-OC, C99, and Aβ dimer without altering the 
level of amyloid processor protein (APP).  (C) Fluorescence intensity of each culture conditions 
were expressed as fold change compared to the TC+ (no Aβ expression) condition. n=7-8, 
*p<0.05 compared to the TC- condition (with Aβ expression). TP70 and α-tocopherol but not 
CP2 or TP67 reduced ROS levels related to intracellular Aβ expression. (This figure was 
reprinted from Maezawa et al.
17
 Journal of Alzheimer's Disease, 2017, accepted in March) 
 
 3.4.2.2 Studies on pharmacokinetics properties 
Figure 3.7 showed pharmacokinetics (PK) properties of TP70. 
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Figure 3.7. Some pharmacokinetics (PK) properties of TP70.  (A) Distribution of TP70 in 
various tissues and plasma after i.p. administration in 3-month-old male WT C57BL/6 mice (25 
mg/Kg body weight) from 0 - 24 h. Shown are the means from three mice per time point.  (B) 
The concentrations of TP70 in plasma following i.v. and p.o. administration. (This figure was 
reprinted from Maezawa et al.
17
 Journal of Alzheimer's Disease, 2017, accepted in March) 
 
Figure 3.7.A showed the distribution of TP70 in seven key organs (including brain, heart, liver, 
lung, kidney, intestine and spleen) together with plasma after i.p. administration from 0.5 - 24 h. 
Ranking after kidney, brain had the second highest TP70 concentration, suggesting that TP70 
overcame blood-brain barrier (BBB) and entered central nervous system (CNS) readily. 
According to Figure 3.7.B, the t1/2 (half time) values of TP70 administered by p.o. and i.v. routes 
were 160 min and 30 min, respectively and the areas under the curve (AUCs) were 678 
75 
(mg•min/L) and 989 (mg•min/L), respectively. Oral bioavailability (F) of TP70 was calculated 
as 678 divided by 989, yielding F = 0.68 and indicating high oral bioavailability. Based on the 
pharmacokinetics (PK) data shown in Figure 3.7, TP70 possesses high oral bioavailability, good 
CNS permeability and suitable oral administered half time. 
 
 3.5 Conclusion 
Nine synthesized tricyclic pyrone compounds were screened for their neuronal protective 
activities against cell death in MC65 cell assay. Six of them (CP2, TP4, TP36, TP70, TP82 and 
TP101) were found to be active with low nanomolar range ED50 values ranging from 0.07 to 
0.26 μM. Among the active compounds, TP70 was found to have dose-dependent response on its 
neuronal protective property. In addition, similar to α-tocopherol, TP70 showed anti-oxidation 
ability, while no such effect was found in CP2. Pharmacokinetics studies of TP70 suggested that 
it can readily penetrate into the brain and have good oral bioavailability. Based on its good 
pharmacokinetics properties and low toxicity, TP70 could be a drug candidate for the treatment 
of AD. 
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Chapter 4 - Chiral-substituted polyvinylpyrrolidones (CSPVP) 
supported Cu/Au nanoclusters and catalytic cyclization of 5-
substituted nona-1,8-dien-5-ols 
 4.1 Background and significance 
In the previous studies reported by the Hua group
1
, a new class of chiral-substituted 
polyvinylpyrrolidones (CSPVP) supported bimetallic nanoclusters were found to be efficient 
catalysts in asymmetric oxidation reactions with broad substrates scopes and high 
enantioselectivities. Based on our previous research
1
, hydroxyl group has been found to be a 
directing group which can lead the asymmetric oxidation. The symmetric 5-substituted nona-1,8-
dien-5-ols were designed as substrates by desymmetrization to study the hydroxyl group-directed 
asymmetric oxidation for the reactive allylic C-H. However, no allylic C-H oxidation product 
was found. Instead, a cyclized lactone product with a stereogenic tetrasubstituted carbon center 
was obtained in the CSPVP supported Cu/Au nanoclusters-hydrogen peroxide oxidation reaction 
(Figure 4.1). This developed a simple and new method to construct stereogenic tetrasubstituted 
carbon centers, which widely existed in natural products
2-4
. More explorations on the CSPVP 
supported Cu/Au nanoclusters catalyzed cyclization reactions are needed to optimize reaction 
conditions. 
  
R OH

O
O
R
Cu/Au-CSPVP 4-24, 
30% H2O2
NO
n
4-24
*
OCHPh2
MW 106000
CSPVP:
 
Figure 4.1. CSPVP supported Cu/Au catalyzed cyclization of 5-substituted nona-1,8-dien-5-
ols. 
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 4.2 Research objectives 
Research objective 1: Study whether the size of the R group on the C-5 stereogenic center of 
chiral-substituted PVPs (CSPVP) would affect the enantioselectivity of the catalytic oxidation 
reactions including the ring closing reactions of substituted nona-1,8-diene-5-ols. 
Research objective 2: Develop a method to create tetrasubstituted carbon stereogenic center 
through catalytic cyclization of 5-substituted nona-1,8-dien-5-ols. 
 
 4.3. Syntheses and characterizations of chiral-substituted 
polyvinylpyrrolidones (CSPVP) for stabilization of Cu/Au nanoclusters in 
catalytic asymmetric oxidation reactions 
 4.3.1 Syntheses of different C-5 chiral-substituted PVP precursors. 
Various C-5 chiral-substituted PVP precursors were synthesized as shown in Figure 4.2. I was 
involved in the syntheses of compounds 4-1 to 4-5, and compound 4-6 was synthesized by Mr. 
Bo Hao, a graduate student in Hua group. Later, it was found that PVP made from precursor 4-6 
was the best polymer stabilizer for Pd/Au or Cu/Au nanoclusters with highest enantioselectivities 
in different kinds of oxidation reactions (Bo Hao et al., 2016
1
). It was found that the size of C-5 
substituted functional groups in the pyrrolidone ring has an effect on the enantioselectivity. 
Generally, the bulkier the size the higher the enantioselectivity produces.
1
 However, too bulky C-
5 substitution, for example t-Bu in compound 4-3 (see Figure 4.2), will prevent the precursor 
from vinylation after de-Boc proctection and eventually lead to failure in polymerization. That 
explained why benzhydryloxymethyl derivative 4-6 was the best C-5 substituted group among 
various functional groups.  
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NO
Boc
O
4-6
NO
Boc
4-5  
Figure 4.2. Chemical structures of various C-5 chiral-substituted PVP precursors. 
 
Syntheses of compounds 4-1, 4-2, 4-3 and 4-5 were shown in Scheme 4.1. Following the 
reported procedure
5-7
, commercial available Boc-protected chiral amino acids were coupled with 
Meldrum’s acid followed by reduction and cyclization to form N-Bocpyrrolidone compounds as 
shown in Scheme 4.1. Possible cyclization mechanism of the formation of pyrrolidone ring was 
shown in Scheme 4.2. The thermal stability of formed five-member pyrrolidone ring was the 
driving force of the cyclization reaction. 
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N
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OHBoc
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4-7
NO R
Boc
N
H
Boc
R
O
OO
NaBH4
N
H
Boc
R
O
OO
O
toluene
reflux
AcOH
CH2Cl2
R = CH2O-t-Bu
4-8
4-9
OO
= isopropyl
= t-Bu
= Naphthylmethyl 4-10
4-11
4-12
4-13
4-14
4-15
4-16
4-17
4-18
4-1 (83% overall yield in three steps)
4-2 (75% overall yield in three steps)
4-3 (85% overall yield in three steps)
4-5 (86% overall yield in three steps)
Meldrum's acid
DCC, DMAP
CH2Cl2
R = CH2O-t-Bu
= isopropyl
= t-Bu
= Naphthylmethyl
R = CH2O-t-Bu
= isopropyl
= t-Bu
= Naphthylmethyl
R = CH2O-t-Bu
= isopropyl
= t-Bu
= Naphthylmethyl
 
Scheme 4.1. Syntheses of compounds 4-1, 4-2, 4-3 and 4-5. 
 
O
OO
O
N
R
Boc
4-a
N
Boc
R O
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heat N
Boc
O R
4-b
H
 
Scheme 4.2. Possible mechanism for the cyclization of pyrrolidone ring. 
 
Synthesis of compound 4-4 was shown in Scheme 4.3. Compound 4-2 was selenylated with 
benzeneselenyl bromide following the reported procedure
8
 to give intermediate 4-19, which was 
further oxidized by sodium periodate in 1,4-dioxane/H2O solution to yield designed alkene 4-4 
via selenoxide elimination. 
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4-2
NO
Boc
a) LDA, THF, -78oC
b) PhSeBr
4-19
NO
Boc
PhSe
yield: 65%
NaIO4
1,4-dioxane/H2O
rt, 1 h
4-4
NO
Boc
yield: 60%  
Scheme 4.3. Synthesis of compound 4-4. 
 
 4.3.2 Synthesis of chiral-substituted polyvinylpyrrolidones (CSPVP)  
(Section 4.3.2 was adapted with permission from Bo Hao et al.
1
 Journal of the American 
Chemical Society 2016, 138, 16839-16848. Copyright © 2016 American Chemical Society.) 
 
The CSPVP (compound 4-24) used in this project was synthesized by Mr. Bo Hao in Hua group 
as shown in Scheme 4.4. To prepare uniform micron-size monodisperse particles
9
, a dispersion 
polymerization method
10
 was used to prepare polymer 4-24. The dispersant, poly(5-substituted 
N-vinylpyrrolidinone-co-vinyl acetate) 4-23 was prepared from the copolymerization reactions 
of respective monomer 4-22 and 1 equiv. of vinyl acetate in the presence of a catalytic amount of 
azobisisobutyronitrile (AIBN) in refluxing acetone. Polymerization of 4-22 separately with a 
catalytic amount of AIBN and in the presence of 1% of respective copolymer 4-23 in DMF at 
120
o
C for 7 days gave polymer 4-24. 
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NO
Boc
 10% TFA
CH2Cl2
50oC, 5 h
NO
H
       4-20 (99% yield)
NaH
Ph2CHBr
NO
H
4-21 (88% yield)
OH OCHPh2
OAc
Na2PdCl4
NO
OCHPh2
O
NO N
O
NO AcO
ml
AIBN
n
4-24 (85% yield); MW 106,000
1% 4-23
  DMF, 120oC
*
1 eq. vinyl acetate
AIBN, acetone
reflux, 30 h
OCHPh2
OCHPh2
OCHPh2
4-1
4-22 (51% yield)
4-23 (83% yield)
4-22
 
Scheme 4.4. Synthesis of C5-benzhydrol substituted chiral PVP polymer. (The Scheme was 
adapted with permission from the supporting information of Bo Hao et al.
1
 Journal of the 
American Chemical Society 2016, 138, 16839-16848. Copyright © 2016 American Chemical 
Society.) 
 
Polymer 4-24 is soluble in water and the molecular weight was determined by gel permeation 
chromatography. Average molecular weight of CSPVP 4-24 is 106,000. Both R- and S-
stereochemistry are likely presented in the stereogenic center (marked with *) in the polymer 
alkane backbone, and they are not identifiable. Presumably, this stereogenic center of the 
polymers can be isotactic, atactic, and syndiotactic,
11
 and likely has lesser effect on the 
asymmetric oxidation reactions. 
 
4.3.3 Syntheses and characterizations of CSPVP supported Cu/Au nanoclusters  
(Section 4.3.3 was adapted with permission from Bo Hao et al.
1
 Journal of the American 
Chemical Society 2016, 138, 16839-16848. Copyright © 2016 American Chemical Society.) 
 
Nanoclusters can be prepared by a number of methods including molecular beams, chemical 
reduction, thermal decomposition, ion implantation, electrochemical synthesis, radiolysis, 
sonochemical synthesis, and biosynthesis, and are characterized by various analytical 
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techniques.
12
 The Hua group has synthesized various bimetallic nanoclusters including Pd/Au 
and Cu/Au, using the chemical reduction method
13
 in the presence of different chiral polymers 
such as 4-24, 4-25 or 4-26 (Figure 4.3). Gold was used due to its high catalytic activity and 
synergistic electronic effects.
13-19
 
NO R1
n
4-24: R1 = CH2OCHPh2; MW 106,000
4-25: R1 = CH2O-t-Bu; MW 68,000
4-26: R1 = CH2Ph; MW 76,000
*
CSPVP
 
Figure 4.3. Chemical structures of chiral-substuted PVP 4-24, 4-25 and 4-26. 
 
For example, a solution of Na2PdCl4 (3 equiv.), HAuCl4 (1 equiv.), and CSPVP 4-24 (0.11 
equiv.; based on the amount of Au) in water was treated with NaBH4 at 25
o
C for 30 min to give a 
light brown to dark grey solution depending on the concentrations. The resulting solution was 
used in the subsequent catalytic reactions without further manipulation. Similarly, Cu/Au (3:1)-
4-24 was also prepared using CuCl (3 equiv.), HAuCl4 (1 equiv.), and CSPVP 4-24 (0.11 equiv.).  
 
The characterizations of nanoclusters were performed by Mr. Bo Hao in Hua group. Various 
characterization methods included inductively coupled plasma-mass spectrometry (ICP-MS), 
transition electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), AFM, DLS and 
IR.
1
 TEM images revealed average diameters of 3.44 ± 1.63 nm and 3.66 ± 1.95 nm for Pd/Au 
(3:1)-4-24 and Cu/Au (3:1)-4-24, respectively. In AFM images, 50 - 200 nm in diameters and ~ 
6 nm in heights of spherical particles were found, and in DLS, 100 - 140 nm sized nanoparticles 
were revealed, suggesting the size of nanocluster-4-24 was ~5 times larger than polymer 4-24, 
and the measured sizes of the particles from AFM and DLS were similar. 
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 4.4 CSPVP supported Cu/Au nanoclusters catalyzed cyclization reaction of 
diene 
 4.4.1 Syntheses of different 5-substituted nona-1,8-dien-5-ols 
Due to limitation of time, I could only complete the syntheses of two 5-substituted nona-1,8-
dien-5-ols (compounds 4-S1 and 4-S2) as shown in Figure 4.4. The synthetic routes were shown 
in Scheme 4.5. A small library of different 5-substituted nona-1,8-dien-5-ols could be obtained 
by replacing 5-position with other functional groups (compound 4-SX, Figure 4.4) following 
similar synthetic procedures.  
OHOH R OH
4-S1 4-S2 4-SX
5-methylnona-1,8-dien-5-ol 5-phenylnona-1,8-dien-5-ol
 
Figure 4.4. Chemical structures of synthesized and proposed 5-substituted nona-1,8-dien-5-
ols. 
 
Syntheses of diene substrates 4-S1 and 4-S2 were shown in Scheme 4.5. Following the reported 
procedure
20
, 3-butenylmagnesium bromide (4-26) underwent nucleophilic addition reaction with 
either ethyl acetate or isopropyl benzoate to form compounds 4-S1 and 4-S2, respectively. 
Br
4-25
Mg/ Et2O
MgBr
4-26
EtOAc
Et2O
isopropyl 
benzoate
Et2O
OH
4-S2 (40% yield)
OH
4-S1 (52% yield)
 
Scheme 4.5. Syntheses of substrates 4-S1 and 4-S2. 
 
 4.4.2 Cyclization experimental procedure 
Reaction conditions were summarized in Table 4.1. 
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Chiral PVP supported Cu/Au nanoclusters was prepared following the reported procedure.
1,13
 A 
solution of 6.5 mg of CuCl and 255 mg of CSPVP 4-24 in 10 mL of DI water was kept stirring 
for 20 min at room temperature until everything was completely dissolved. Allowed it to cool to 
0
o
C, 2.19 mL of HAuCl4
.
3H2O (c = 10 mmol/L) stock solution was added, followed by 9 mg of 
NaBH4. Reaction solution turned to be dark grey immediately after adding NaBH4. Resulting 
reaction solution was kept stirring at 0
o
C for another 30 min. 
 
After forming CSPVP-Cu/Au nanoclusters, 10 mL of acetonitrile, 338 mg of compound 4-S1 
and 2.2 mL of (w/w) 30% H2O2 aqueous solution were added to the solution at 0
o
C. Allowed it 
to warm to room temperature and kept stirring at 50
0
C. Reaction was tracked through Thin-layer 
chromatography (TLC) and 
1
HNMR. Temperature was increased to 60
0
C after 24 h and reaction 
was stopped after 8 days although small amount of starting material 4-S1 was left behind. 
 
Reaction was diluted with 10 mL of distilled water and extracted with dichloromethane five 
times. Combined organic layers were washed with brine, dried over MgSO4, filtered 
concentrated and distilled off solvents. The concentrated residue was column chromatographed 
on silica gel using a gradient mixture of hexane and diethyl ether as eluent to give 22 mg (6% 
yield without counting starting material recovery; 7% yield with counting starting material 
recovery) of lactone product 4-L as light yellow liquid. 
 
OH O
O
Cu/Au-CSPVP, 
30 %H2O2, 
CH3CN/DI water
60 oC,8days
4-S1
NO
n
4-24
*
OCHPh2
4-L
(6% yield, 43% ee)
MW 106000
CSPVP:
 
Reagent (Molecular 
Weight) 
Equivalent mmol Weight Volume 
4-S1 (154) 1 eq. 2.19 mmol 338 mg  
CuCl (99) 0.03 eq. 0.066 mmol 6.5 mg  
HAuCl4
.
3H2O 
(393.8) 
0.01 eq. 0.0219 mmol  
2.19 mL (c = 10 
mM/L) 
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CSPVP 4-24 
(106000) 
0.0011 eq. 0.0024 mmol 255 mg  
NaBH4 (38) 0.1 eq. 0.219 mmol 9 mg  
(w/w) 30% H2O2 
(34.01) 
10 eq. 21.9 mmol 2.48 g 
2.2 mL (d=1.110 
g/mL) 
CH3CN    10 mL 
DI water    10 mL 
Table 4.1. Reaction conditions of CSPVP-Cu/Au nanoclusters catalyzed cyclization of 5-
methylnona-1,8-dien-5-ol (compound 4-S1). 
 
 4.5 Discussion 
 4.5.1 Results, discussion and product characterization. 
After 8 days reaction, got 22 mg of lactone product 4-L, 28 mg of recovered starting material 4-
S1. Most of the reacted starting material 4-S1 went through polymerization to form 150 mg of 
byproduct polymer, which led to low yield (6% yield) of cyclized lactone. Compound 4-L was 
characterized by 
1
HNMR, 
13
CNMR, and MS as described in section 4.7.2.11. The regiochemistry 
of compound 4-L was analyzed by 2D correlation spectroscopy (COSY) NMR as shown in 
Figure 4.5. In COSY spectrum, the signals at 2.48 -2.7 ppm (2H) assigned for C3-hydrogens 
showed correlation with C4-hydrogens at 1.91 - 2.04 ppm (2H); signals at 1.66-1.84 ppm (2H) 
assigned for C6-hydrogens showed correlation with C7-hygrogens at 2.04 - 2.21 ppm (2H); 
signals at 5.70 -5.90 ppm (1H) assigned for C8-hydrogen showed correlation with C9-hydrogens 
at 4.82 - 5.18 ppm (2H); singlet at 1.39 ppm (3H) assigned for the methyl hydrogens had no 
correlation with other protons. The % ee of compound 4-L was determined by HPLC using 
chiral column, Chiralpak AD(-H) column, n-hexane : i-PrOH = 93:7, flow rate: 0.3 mL/min; t1 = 
53 min and t2 = 56 min. HPLC analysis was carried out by Mr. Bo Hao in the Hua group and the 
result was shown in Figure 4.6. Optical purity of obtained compound 4-L was 44% ee. However, 
the configurations of two enantiomers couldn’t be assigned at this time.  
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Figure 4.5. 
1
H-
1
H COSY spectrum of compound 4-L. 
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Figure 4.6. Optical purity of obtained compound 4-L was determined by HPLC. (HPLC 
analysis was carried out by Mr. Bo Hao in the Hua group.) 
 
 4.5.2 Concerns  
The advantages of this method are catalytic asymmetric cyclization, creating a quaternary carbon 
stereogenic center in one step and easy synthetic approach to obtain the Cu/Au nanoclusters. The 
chemical yields and enantioselectivities of the reactions have been improved significantly by Mr. 
Bo Hao after my initial study (notably, compound 4-S2 provided 95% ee with 75% yield of the 
cyclized product). The big improvement was achieved by using different chiral-substituted PVP 
(CSPVP) to stabilize Cu/Au nanoclusters and different substrates such as 4-S2. Apparently, by 
introducing bulkier functional group in C3 and C4 positions of CSPVP, better reaction yields and 
enantioselectivities were obtained. 
 
 4.5.3 Future work 
The catalytic cyclization of diene substrate 4-S2 is being conducted by Mr. Bo Hao. Much better 
reaction yields and enantioselectivities have been obtained by using different CSPVP as 
discussed in section 4.5.2. Reaction temperature was optimized to 50
0
C with shorter reaction 
time (three days). Exploration on a broader substrate scope (Figure 4.4, 4-SX) could be 
performed in the future under the optimized reaction conditions. Inspired by the discovery that 
introducing bulkier functional group in C3 and C4 positions of CSPVP could increase 
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enantioselectivity and reaction yield, introducing bulkier substitutions in 5-substituted nona-1,8-
dien-5-ols could be attempted to further increase reaction yield. We hypothesize that the C-5 
methyl group in 4-S1 is too small for the stereoselective desymmetrization reaction. As shown in 
Figure 4.7, the C(4)-C(5)-O(11) and C(6)-C(5)-O(11) bond-angle values of compounds 4-S1 and 
4-S2 were calculated by Chem-3D based on their predicted minimized energy models. The 
smaller C-C-O bond angle decreased from 109.159
o
 to 107.107
o
 when C5-position was 
substituted by bigger phenyl group. In other words, the bulkier C-5 substitution pushed -OH 
group more towards double bond, which could have a higher chance to go through cyclization 
considering hydroxyl group directing the oxidation
1
.  
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Figure 4.7. Chem-3D calculated C(4)-C(5)-O(11) and C(6)-C(5)-O(11) bond-angle values on 
minimized energy models of compounds 4-S1 and 4-S2. 
 
 4.6 Conclusion 
A five-member cyclized lactone possessing a stereogenic tetrasubstituted carbon center was 
formed in a one-step Cu/Au nanoclusters-hydrogen peroxide oxidation reaction. This developed 
a novel and simple method to synthesize tetrasubstituted carbon stereogenic center. Significant 
improvement of reaction yields and enantioselectivities were achieved by introducing bulkier 
substitution in C3 and C4 positions of CSPVP according to updates from ongoing research. 
 
 4.7 Synthetic experimental procedures  
 4.7.1 General 
Chemicals were purchased from Fisher Scientific and VWR international LLC and Chem-Impex 
International, Inc.. NMR spectra were taken from a 400 MHz Spectrometer (Varian Inc.) in 
chloroform-D unless otherwise informed. Mass spectra were obtained from an API 2000-triple 
quadrupole ESI-MS/MS mass spectrometer (Applied Biosystems). 
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 4.7.2 Representative synthesis 
(Descriptions of syntheses of compounds 4-11, 4-15 and 4-1 were reprinted with permission 
from the supporting information of Bo Hao et al.
1
 Journal of the American Chemical Society 
2016, 138, 16839-16848. Copyright © 2016 American Chemical Society.) 
 
 4.7.2.1 (S)-tert-Butyl 3-tert-butoxy-1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-1-
oxopropan-2-ylcarbamate (Compound 4-11)
5-7
 
N
H
Boc
O
O
OO
OO
4-11  
A solution of 4.0 g (15.3 mmol) of N-Boc-O-tert-butyl-L-serine, 3.3 g (23 mmol) of Meldrum’s 
acid (2,2-dimethyl-1,3-dioxane-4,6-dione), and 2.8 g (22.9 mmol) of 4-(dimethylamino)pyridine 
(DMAP) in 80 mL of dichloromethane under argon was cooled to 0
o
C over an ice-water bath. To 
it, a solution of 3.47 g (16.8 mmol) of N,N’-dicyclohexylcarbodiimide (DCC) in 20 mL of 
dichloromethane was added dropwise. The mixture was stirred for 12 hours under argon and the 
precipitated (N,N’-dicyclohexylurea) was removed by filtration.  The filtrate was washed with 50 
mL of 5% HCl, and then water, dried (anhydrous Na2SO4), and concentrated to dryness leaving 
5.83 g of compound 4-11 as a white solid. This compound was used in the following step 
without further purification. 
1
H NMR  ppm 5.67 – 5.63 (m, 1 H), 5.49 – 5.47 (m, 1 H), 3.74 – 
3.70 (m, 2 H), 3.62 (s, 1 H, NH), 1.76 (s, 3 H), 1.73 (s, 3 H), 1.46 (s, 9 H), 1.26 (s, 9 H). 
13
C 
NMR  ppm 206.8, 172.7, 152.3, 105.9, 79.0, 75.0, 62.0, 60.6, 59.9, 30.0 (3 C), 28.4 (3 C), 25.6 
(2 C).  MS (positive mode), m/z calcd for C18H30NO8 (M+H)
+
 388.2, found 388.7. 
 4.7.2.2 (R)-tert-Butyl 3-tert-butoxy-1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)propan-
2-ylcarbamate (Compound 4-15) 
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N
H
Boc
O
O
OO
4-15
O
 
To a cold (0
o
C) solution of 5.80 g (15.2 mmol) of compound 4-11 in 150 mL of dichloromethane 
under argon were added 5.51 g (91.8 mmol) of acetic acid and 1.51 g (39.8 mmol) of NaBH4.  
The solution was stirred at 0
o
C for three hours and at 25
o
C for 12 hours, diluted with 30 mL of 
water, the dichloromethane layer was separated, and the water layer was extracted with 
dichloromethane three times. The combined organic layers were washed with water and brine, 
dried (anhydrous Na2SO4), concentrated to give a yellow oil, which was crystallized from diethyl 
ether to give 5.27 g of compound 4-15 as a white solid. 
1
H NMR  ppm 5.08 – 5.09 (m, 1 H), 
4.08 – 4.00 (m, 1 H), 3.62 (s, 1 H, NH), 3.45 – 3.41 (m, 2 H), 2.5 – 2.45 (m, 1 H), 2.16 – 2.01 
(m, 1 H), 1.80 (s, 3 H), 1.72 (s, 3 H), 1.40 (s, 9 H), 1.05 (s, 9 H); 
13
C NMR  ppm 208.0, 174.6, 
151.0, 105.7, 79.3, 74.7, 69.8, 49.6, 47.1, 31.9, 28.4, 25.7.  MS (positive mode), m/z calcd for 
C18H32NO7 (M+H)
+
 374.2, found 374.0. 
 4.7.2.3 (R)-N-(tert-Butoxycarbonyl)-5-(tert-butoxymethyl)-pyrrolidin-2-one 
(Compound 4-1) 
NO
Boc
O
4-1  
A solution of 5.26 g (14.10 mmol) of compound 4-13 in 40 mL of toluene under argon was 
heated to reflux for 6 hours, cooled to 25
o
C, concentrated under vacuum, and column 
chromatographed on silica gel using hexane and ethyl acetate (4:1) as eluent to give 3.44 g (83% 
overall yield in three steps) of compound 3 as a yellow oil. 
1
H NMR  ppm 4.09 – 4.07 (m, 1 H), 
3.52 (dd, J = 10, 4 Hz, 1 H), 3.31 (dd, J = 10, 1.6 Hz, 1 H), 2.56 (dt, J = 17.6, 9.6 Hz, 1 H), 2.20 
(dd, J = 17.6, 9.2 Hz, 1 H), 2.05 – 1.84 (m, 2 H), 1.40 (s, 9 H), 1.02 (s, 9 H). 13C NMR  ppm 
175.3, 150.1, 82.6, 73.2, 62.9, 58.0, 32.5, 28.2, 27.5, 21.7.  MS (positive mode), m/z calcd for 
C14H26NO4 (M+H)
+
 272.2, found 272.0. 
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 4.7.2.4 (R)-tert-Butyl 2-isopropyl-5-oxopyrrolidine-1-carboxylate (Compound 4-2) 
NO
Boc
4-2  
Following similar procedure described before (see sections 4.7.2.1 to 4.7.2.3), instead of N-Boc-
O-tert-butyl-L-serine, started from 3.9 g (18 mmol, 1eq.) of Boc-L-valine in the beginning and 
produced 3.08 g (75% overall yield in three steps) of product 4-2 as light yellow oil. 
1H NMR δ 
ppm 0.83 (d, J = 7.03 Hz, 3 H) 0.92 (d, J = 7.03 Hz, 3 H) 1.50 (s, 9 H) 1.74 - 1.86 (m, 1 H) 1.89 - 
2.06 (m, 1 H) 2.12 - 2.27 (m, 1 H) 2.32 - 2.57 (m, 2 H) 3.98 - 4.12 (m, 1 H). 
13
C NMR δ ppm 
175.1, 150.4, 82.9, 62.7, 32.5, 30.8, 28.2 (3C), 19.2, 18.2, 16.0.  MS (positive mode), m/z calcd 
for C12H21NO3Na (M+Na)
+
 250.1, found 250.3. 
 4.7.2.5 (R)-tert-Butyl 2-tert-butyl-5-oxopyrrolidine-1-carboxylate (Compound 4-3) 
NO
Boc
4-3  
Following similar procedure described before (see sections 4.7.2.1 to 4.7.2.3), instead of N-Boc-
O-tert-butyl-L-serine, started from 3 g (13 mmol, 1eq.) of Boc-Tle-OH in the beginning and 
produced 2.7 g (85% overall yield in three steps) of product 4-3 as light yellow oil. 
1H NMR δ 
ppm 0.74 (s, 9 H) 1.34 (s, 9 H) 1.66 - 2.03 (m, 2 H) 2.13 - 2.45 (m, 2 H) 3.93 (d, J = 8.98 Hz, 1 
H). 13C NMR δ ppm 175.2, 150.8, 82.7, 65.0, 36.9, 32.6, 27.8 (3C), 26.3 (3C), 20.2.  MS 
(positive mode), m/z calcd for C13H23NO3Na (M+Na)
+
 264.2, found 264.4. 
 4.7.2.6 (R)-tert-Butyl 2-((naphthalen-1-yl)methyl)-5-oxopyrrolidine-1-carboxylate 
(Compound 4-5) 
NO
Boc
4-5  
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Following similar procedure described before (see sections 4.7.2.1 to 4.7.2.3), instead of N-Boc-
O-tert-butyl-L-serine, started from 900 mg (2.85 mmol, 1eq) of Boc-L-1-Naphthylalanine in the 
beginning and produced 792 mg (86% overall yield in three steps) of product 4-5 as light yellow 
oil. 
1H NMR δ ppm 1.57 (s, 9 H) 1.73 - 1.88 (m, 2 H) 2.27 - 2.45 (m, 1 H) 2.48 - 2.69 (m, 1 H) 
2.93 (dd, J=13.47, 10.35 Hz, 1 H) 3.80 (dd, J=13.50, 4.10 Hz, 1 H) 4.50 - 4.69 (m, 1 H) 7.15 - 
7.64 (m, 4 H) 7.76 (d, J=8.20 Hz, 1 H) 7.85 (d, J=8.20 Hz, 1 H) 8.26 (d, J=8.20 Hz, 1 H). 
 4.7.2.7 (5R)-tert-Butyl 5-isopropyl-2-oxo-3-(phenylselanyl)pyrrolidine-1-carboxylate 
(Compound 4-19)
8
  
4-19-1
NO
Boc
PhSe
NO
Boc
PhSe
4-19-2
NO
Boc
PhSe
4-19
 
To a solution of 1.18 g (5.19 mmol, 1eq.) of compound 4-2 in16 mL of distilled THF at -78
o
C, 
5.7 mmol (1.1 eq.) of lithium diisopropylamide (LDA) solution was added dropwise and the 
resulting solution was kept stirring under argon at -78
o
C for 1h. To it, a solution of 1.28g (5.4 
mmol, 1.05 eq.) of phenylselenyl bromide in 13 mL of distilled THF was added dropwise and 
resulting reaction solution was kept stirring under argon at -78
o
C for another 15 min. Reaction 
solution was quenched with saturated NH4Cl aqueous solution, diluted with distilled water, 
extracted with dichloromethane three times. Combined organic layers were washed with brine, 
dried over Na2SO4, filtered, concentrated and column chromatographed on silica gel using a 
gradient mixture of hexane and ethyl acetate as eluent to produce 1.3 g (65% yield) of compound 
4-19 as yellow solid. Note: Compound 4-19 is a mixture; the major product was 4-19-1 while 
small amount 4-19-2 mixed inside. The 65% reaction yield was calculated based on the recovery 
of mixture 4-19. 
1H NMR δ ppm 0.79 (d, J = 6.64 Hz, 3 H) 0.86 (d, J = 6.64 Hz, 3 H) 1.51 (s, 9 
H) 1.96 - 2.11 (m, 1 H) 2.16 - 2.30 (m, 2 H) 3.79 - 3.88 (m, 1 H) 3.90 - 4.04 (m, 1 H) 7.26 - 7.37 
(m, 3 H) 7.60 - 7.74 (m, 2 H). 4-19-2: 
1H NMR δ ppm 0.67 (d, J = 7.03 Hz, 3 H) 0.86 (d, J = 7.03 
Hz, 3 H) 1.52 (s, 9 H) 1.78 - 1.92 (m, 1 H) 2.30 - 2.53 (m, 2 H) 3.87 - 4.04 (m, 2 H) 7.26 - 7.35 
(m, 3 H) 7.64 - 7.71 (m, 2 H). 
 4.7.2.8 (S)-tert-Butyl 2-isopropyl-5-oxo-2H-pyrrole-1(5H)-carboxylate (Compound 4-
4) 
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NO
Boc
4-4  
To a solution of 1.34 g (3.5 mmol, 1 eq.) of compound 4-19, in 18 mL of 1,4-dioxane and 2 mL 
of distilled water, 975 mg (4.6 mmol, 1.3 eq.) of sodium periodate was added. The resulting 
reaction mixture was kept stirring vigorously at room temperature for 1 h. Diluted reaction 
mixture with 40 mL of 5% ammonium hydroxide solution and extracted with diethyl ether three 
times. Combined organic layers were washed with water, brine, dried over Na2SO4 , filtered, 
concentrated and column chromatographed on silica gel using a gradient mixture of hexane and 
ethyl acetate as eluent to give 470 mg (60% yield) of compound 4-4 as colorless oil. 
1
H NMR δ 
ppm 0.67 (d, J = 7.03 Hz, 3 H) 1.10 (d, J = 7.03 Hz, 3 H) 1.55 (s, 9 H) 2.48 - 2.71 (m, 1 H) 4.45 - 
4.65 (m, 1 H) 5.37 - 7.90 (m, 6 H) 6.14 (dd, J = 6.05, 2.10 Hz, 1 H) 7.12 (dd, J = 6.05, 2.10 Hz, 1 
H). 
13C NMR δ ppm 169.7, 149.8, 148.0, 128.0, 83.1, 67.5, 29.1, 28.3 (3C), 19.7, 15.1.  MS 
(positive mode), m/z calcd for C12H19NO3Na (M+Na)
+
 248.1, found 248.2. 
 4.7.2.9 5-Methylnona-1,8-dien-5-ol (Compound 4-S1)20 
OH
4-S1  
To 3-butenylmagnesium bromide (4-26) prepared from 2.66 g (19.7 mmol, 2 eq.) of 4- bromo-1-
butene (4-25) and 520 mg (21.7 mmol, 2.2 eq.) of magnesium in distilled diethyl ether at 0
o
C, 
was added dropwise 867 mg (9.8 mmol, 1 eq.) of distilled ethyl acetate under argon. After 1 h 
stirring at room temperature under argon, the resulting reaction solution was quenched with 
saturated NH4Cl aqueous solution, adjusted to pH around 2 to 3 using 2 N HCl aqueous solution 
and extracted with diethyl ether. Combined organic layers were washed with brine, dried over 
MgSO4, filtered and distilled off most solvents. The concentrated residue was column 
chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as eluent to 
give 800 mg (52% yield) of compound 4-S1 as colorless liquid. 
1
H NMR δ ppm 1.18 (s, 3 H) 
1.32 (s, 1 H) 1.44 - 1.69 (m, 4 H) 1.94 - 2.23 (m, 4 H) 4.76 - 5.21 (m, 4 H) 5.72 - 5.98 (m, 2 H). 
13
C NMR  ppm 139.1 (2C), 114.6 (2C), 72.7, 41.1 (2C), 28.5 (2C), 27.0.  MS (positive mode), 
m/z calcd for C10H18ONa (M+Na)
+
 177.1, found 177.1. 
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 4.7.2.10 5-Phenylnona-1,8-dien-5-ol (Compound 4-S2) 
OH
4-S2  
To 3-butenylmagnesium bromide (4-26) prepared from 1.33 g (9.85 mmol, 2 eq.) of 4- bromo-1-
butene (4-25) and 260 mg (10.8 mmol, 2.2 eq.) of magnesium in distilled diethyl ether at 0
o
C, 
was added dropwise 808 mg (4.92 mmol, 1 eq.) of distilled isopropyl benzoate under argon. 
After 1 h stirring at room temperature under argon, the resulting reaction solution was quenched 
with saturated NH4Cl aqueous solution, adjusted to pH around 2 to 3 using 2 N HCl aqueous 
solution and extracted with diethyl ether. Combined organic layers were washed with brine, 
dried over MgSO4, filtered and distilled off most solvents. The concentrated residue was column 
chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as eluent to 
give 420 mg (40% yield) of compound 4-S2 as colorless liquid. 
1
H NMR δ ppm 1.69 - 2.21 (m, 8 
H) 4.85 - 5.04 (m, 4 H) 5.62 - 5.90 (m, 2 H) 7.09 - 7.57 (m, 5 H). 
13
C NMR  ppm 145.8, 139.0 
(2C), 128.4 (2C), 126.7, 125.5 (2C), 114.8 (2C), 77.4, 42.4 (2C), 28.2 (2C).  MS (positive mode), 
m/z calcd for C15H21O (M+H)
+
 217.1, found 218.1. 
 4.7.2.11 5-(But-3-enyl)-dihydro-5-methylfuran-2(3H)-one (Compound 4-L) 
O
O
4-L  
Reaction was performed as described in section 4.4.2.Started from 338 mg of compound 4-S1 
and obtained 22 mg (6% yield) of product 4-L as light yellow liquid. 
1
H NMR δ ppm 1.39 (s, 3 
H) 1.66 - 1.84 (m, 2 H) 1.91 - 2.21 (m, 4 H) 2.48 - 2.70 (m, 2 H) 4.82 - 5.18 (m, 2 H) 5.70 - 5.90 
(m, 1 H). 
13
C NMR  ppm 176.8, 137.7, 115.3, 86.6, 40.2, 33.2, 29.3, 28.3, 25.8.  MS (positive 
mode), m/z calcd for C9H14O2Na (M+Na)
+
 177.1, found 177.0. 
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Appendix A - 
1
H-NMR and 
13
C NMR spectra 
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